Mission Statement
To contribute to the improvement of the health of children and youth in Canada by national surveillance and research into uncommon paediatric diseases and conditions.

For more information on the Canadian Paediatric Surveillance Program, please contact:

Canadian Paediatric Society
Andrea Medaglia, CPSP Senior Coordinator
2305 St. Laurent Blvd.
Ottawa, Ont. K1G 4J8
Tel.: 613-526-9397, ext. 239; Fax: 613-526-3332
E-mail: cpsp@cps.ca; http://www.cps.ca/english/cpsp

Canada Post Publications Agreement number 40006512
# Table of Contents

2 Acknowledgements  
3 Foreword  
  3 Federal Minister of Health, Health Canada  
  3 Director General, Centre for Infectious Disease Prevention and Control  
  4 President of the Canadian Paediatric Society  
  4 CPSP Chairman  
5 CPSP Steering Committee  
5 CPSP Working Group  
6 Publications  
  6 Published papers related to studies  
  7 Highlights published in *Paediatrics & Child Health*  
8 Presentations  
10 Funding  
11 Surveillance at Work  
  11 Overview  
  14 Investigators’ corner  
  15 Studies timeline  
16 Surveillance Studies in 2001  
  16 Acute flaccid paralysis  
  19 Anaphylaxis  
  22 Cerebral edema in diabetic ketoacidosis  
  25 CHARGE association/syndrome  
  29 Congenital rubella syndrome  
  31 Hemolytic uremic syndrome  
  34 Hepatitis C virus infection  
  36 Necrotizing fasciitis  
  38 Neonatal herpes simplex virus infection  
  41 Neonatal liver failure/perinatal hemochromatosis  
  43 Progressive intellectual and neurological deterioration  
  45 Smith-Lemli-Opitz syndrome  
47 New Studies in 2002  
  47 Adverse drug reactions  
  47 Neonatal hyperbilirubinemia – severe  
  48 Prader-Willi syndrome  
  49 Vitamin D deficiency rickets  
51 International Developments  
  53 Highlights from other national paediatric surveillance units
Acknowledgements

The key strengths of the CPSP continue to be the participation of Canadian paediatricians, subspecialists and other health-care providers in the monthly collection of information on rare paediatric conditions, our principal investigators who review and analyze the data collected to provide us with knowledge and educational solutions to help children and youth around the world, and our Steering Committee members who continue to guide the program.

For their role in the verification of data collected, we thank:
- Canadian Association of Paediatric Health Centres/Canadian Paediatric Decision Support Network
- IMPACT (Immunization Monitoring Program ACTive) centres
- Notifiable Diseases Reporting System, Centre for Infectious Disease Prevention and Control, Health Canada
- CJD-Surveillance System Canada
- Canadian Institute for Health Information

We also gratefully acknowledge the financial support from all our funders, a summary of which is found in this report.

The strong CPSP partnership between the Canadian Paediatric Society (CPS) and Health Canada’s Centre for Infectious Disease Prevention and Control (CIDPC) allows the program to grow in Canada and to take its proper place on the international scene.

A Special Tribute to Dr. John Waters

It was Dr. John Waters who first brought news of the British Paediatric Surveillance Unit to the CPS Infectious Diseases and Immunization Committee in 1995. His enthusiasm for this type of active paediatric surveillance program was infectious and Dr. Victor Marchessault, then Executive Vice-President of the CPS, brought the idea to Drs. Philippe Duclos and Paul Sackett at Health Canada. Thus, the Canadian Paediatric Surveillance Program was born in 1996.

It was a sad day, on July 6, 2001, when Dr. John Waters passed away after a five-and-a-half-year battle with cancer. His dedication to public health, his passion for communicable disease control and immunization, and his diligence to translate good ideas into real programs that benefit kids are but a few of the praises from his colleagues.

He was a remarkable man. We will indeed miss his vision, commitment, honesty, professionalism, and deep caring for children and youth.
Foreword

Federal Minister of Health, Health Canada

Canada’s children are our future, and Health Canada is committed to ensuring that all of Canada’s children are given the best possible start in life. Programs such as the Canadian Paediatric Surveillance Program (CPSP) help us to fulfill our commitment. The CPSP was created to enable the collection of vital data in the study of rare diseases of Canadian children and youth.

The work of this surveillance system reaches well beyond our Canadian borders to capture the best possible information to increase our knowledge on childhood diseases.

Congratulations to the CPSP for being a founding member of the International Network of Paediatric Surveillance Units. Through this network, established in 1998, the participation of paediatricians from around the world has advanced our knowledge about uncommon childhood infections and disorders.

As federal Minister of Health, I commend the efforts of the CPSP. This program is a result of an ongoing partnership with Health Canada and the Canadian Paediatric Society. I want to take this opportunity to thank those front-line paediatricians who take the time to return the monthly report – the act of which gives true meaning to “active surveillance”. On behalf of all Canadians, I wish the Canadian Paediatric Surveillance Program many more years of continued success.

Director General, Centre for Infectious Disease Prevention and Control

I am pleased to accept the sixth annual report of the Canadian Paediatric Surveillance Program.

This year has proven successful in promoting paediatric surveillance, both at home and abroad. Visionaries, such as the late Dr. John Waters, had the foresight to know that establishing surveillance units in several countries would afford greater opportunities for collaborative studies which, in turn, would result in an increased knowledge and understanding of rare paediatric diseases. Accordingly, Canada hosted the inaugural meeting of the International Network of Paediatric Surveillance Units (INoPSU) in June 2000 and actively participated in the second meeting in April 2002, hosted by the United Kingdom.

All too often in certain regions of the world, the lives of children are compromised by violence and political strife. Canada has a responsibility to ensure that public health actions arising from CPSP and INoPSU collaborative studies help to improve the lives of all children throughout the world. The health and well-being of children today should benefit from knowledge generated through surveillance.
President of the Canadian Paediatric Society

It is astonishing how quickly and profoundly the world around us can change. Words such as anthrax, smallpox, and bioterrorism have entered everyday conversation around the dinner table and in the workplace, and there is a climate of uncertainty that is without precedent. Whether it’s at airport check-ins, within our major institutions, in the agriculture industry, in the early recognition and containment of communicable diseases, or in bringing a clearer understanding to disorders that most of us will never see, “surveillance” has taken on new meaning. In general, organizations such as the centres for disease control, the American Academy of Pediatrics, the Canadian Paediatric Society, and many others have responded admirably to the demand by the public at large for information.

There is a certain irony that the formation of the Canadian Paediatric Surveillance Program was prompted by the need to validate Canada’s population-based immunization programs. Although the focus has broadened considerably during the six years since its inception, the overall strategy remains simple, yet highly effective. The “check-off” form that we all receive each month lies at its heart, making the practising paediatrician the key member of the entire national surveillance team! Congratulations to everyone who has contributed to the success of this important program as we enter a new era in global surveillance.

CPSP Chairman

This will be my last report as the chairman of the CPSP; my terms of office have come to an end. Looking back, I see the growth of our surveillance program from a pilot project with three studies to the well-established, high-profile program that it is today.

The Steering Committee continues to refine the program guidelines and provide expertise and guidance to principal investigators wishing to use the program for their studies. This year, we have expanded the opportunities available by allowing investigators to survey participants on a one-time-basis to determine the prevalence of a problem or to answer a specific question on practice experience.

We have been busy disseminating our findings in an effort to showcase the value of active surveillance and to keep participants engaged in the program. As evidence of the program’s achievements, I encourage you to peruse the list of publications and presentations in this report.

Looking forward to 2002, we are pleased that a concurrent session on the public health and clinical implications of the CPSP was approved for the CPS annual meeting in Toronto.

In closing, I wish the CPSP and the new chairman, Dr. Gilles Delage, even greater progress and success. Thank you to all who have made my participation in the program such a rewarding experience.
CPSP Steering Committee

Dr. Richard Stanwick                       Chairman, Canadian Paediatric Society
Dr. Ronald Barr/Dr. Lynne Warda            Canadian Paediatric Society
Ms. Marie Adèle Davis                     Canadian Paediatric Society
Dr. Gilles Delage                         Incoming Chairman, Canadian Paediatric Society
Ms. Jo-Anne Doherty                       Centre for Infectious Disease Prevention and Control, Health Canada
Dr. Danielle Grenier                      Medical Affairs Officer, Canadian Paediatric Society
Dr. Richard Haber                         Canadian Paediatric Society
Dr. Jack Holland/Dr. Rick Cooper          Assembly of Canadian University Paediatric Department Heads
Dr. Daniel Keene/Dr. Simon Levin          Liaison, Canadian Association of Child Neurology
Dr. Arlene King                           Centre for Infectious Disease Prevention and Control, Health Canada
Dr. Susan King                            Canadian Paediatric Society
Dr. Victor Marchessault                   Honourary member, CPSP INoPSU representative
Dr. Catherine McCourt                     Centre for Healthy Human Development, Health Canada
Ms. Andrea Medaglia                       Senior Program Coordinator, Canadian Paediatric Society
Dr. Jeff Scott                            Council of Chief Medical Officers of Health
Dr. Paul Sockett                          Consultant, Centre for Infectious Disease Prevention and Control, Health Canada
Dr. Anne Summers                          Liaison, Canadian College of Medical Geneticists
Dr. Wendy Vaudry                          IMPACT (Immunization Monitoring Program ACTive)
Dr. John Waters                           Canadian Paediatric Society
Dr. John Watts                            Canadian Paediatric Society

CPSP Working Group

Ms. Andrea Medaglia                       Senior Program Coordinator (Chair), Canadian Paediatric Society
Ms. Marie Adèle Davis                     Executive Director, Canadian Paediatric Society
Ms. Jo-Anne Doherty                       Chief, Division of Disease Surveillance, Centre for Infectious Disease Prevention and Control, Health Canada
Dr. Danielle Grenier                      Medical Affairs Officer, Canadian Paediatric Society
Publications

Published papers related to studies

(See www.cps.ca/english/CPSP for hotlinks to abstracts)


Real-time reporting of anaphylaxis in infants, children and adolescents by physicians involved in the Canadian Paediatric Surveillance Program. Simons FER, Chad ZH, Gold M. *Journal of Allergy and Clinical Immunology* 2002;109:S181

Genetics and the Canadian Paediatric Surveillance Program. Summers A. *Paediatr Child Health* 2001;6(5):269-70

The Canadian Paediatric Surveillance Program: Beyond collecting numbers. Doherty J, Grenier D. *Paediatr Child Health* 2001;6(5):263-8


The Canadian Paediatric Surveillance Program: Surveillance that works! Waters JR. *Paediatr Child Health* 2001;6(5):233-4


Following up on unfinished business – prenatal rubella screening and postpartum vaccination. Tam T. CMAJ 1998;159(9):1117-8


**Highlights published in Paediatrics & Child Health**


Surveillance case definitions and clinical diagnoses. Paediatr Child Health 2001;6(9):651

Commitment to patient confidentiality. Paediatr Child Health 2001;6(8):521


Call for new studies. Paediatr Child Health 2001;6(6):346

Pertinence of the CPSP to emergency medicine specialists. Paediatr Child Health 2001;6(5):241

Hemorrhagic disease of the newborn: Is there a risk in not following recommended guidelines? Paediatr Child Health 2001;6(4):183

A new study on hepatitis C: What it means to me. Paediatr Child Health 2001;6(3):137

‘Do I complete the monthly reporting form or toss it away?’ Paediatr Child Health 2001;6(2):83

Congenital rubella syndrome: The need for standing orders for vaccination of susceptible women. Paediatr Child Health 2001;6(1):10

Presentations

(See www.cps.ca/english/CPSP for hotlinks to abstracts)


Canadian Paediatric Surveillance Program (CPSP):
Clinical implications. Doherty J, Medaglia A, Grenier, D. *Paediatr Child Health* 2001;6 Suppl A:17A.

Canadian Paediatric Surveillance Program.


**Funding**

To date, funding for the surveillance program has been made available from the Centre for Infectious Disease Prevention and Control, Health Canada, as well as other government departments, organizations and companies interested in increased knowledge of uncommon childhood conditions and the practical improvement in prevention and treatment.

Funding is required to cover core requirements, such as administrative costs pertaining to the program (including the salary of a full-time program coordinator, a full-time administrative assistant, a part-time medical advisor as well as part salaries for administrative and financial support) and the cost of identifying, in an effective and timely manner, and then obtaining follow-up data on rare conditions and diseases. Reporting is also an important aspect of the program.

Educational grants are welcome from all interested in monitoring and contributing to the improvement of health of all Canadian children and youth.

We gratefully acknowledge funding from the following sources:

**Government departments, Health Canada:**
- Population and Public Health Branch
- Centre for Healthy Human Development
  - Health Surveillance and Epidemiology Division (formerly Bureau of Reproductive and Child Health)
- Centre for Infectious Disease Prevention and Control
  - Division of Bloodborne Pathogens
  - Division of Disease Surveillance
  - Division of Enteric, Foodborne and Waterborne Diseases
  - Division of Immunization
  - Division of Sexual Health Promotion and STD Prevention and Control
- Hepatitis C Division
- Health Products and Food Branch
- Food Directorate

**Non-governmental sources:**
- Anaphylaxis Foundation of Canada
- Canadian Allergy, Asthma and Immunology Foundation
- Canadian Diabetes Association
- CHARGE Syndrome Foundation, Inc.
- Children's Hospital of Eastern Ontario Research Institute
- Coady Family Fund for Liver Research
- Dairy Farmers of Canada
- GlaxoSmithKline
- Hamilton Health Science Foundation
- IWK Health Centre
- Mead Johnson & Company
- Merck Frosst Canada & Co.

We also acknowledge Cistel Technology Inc. for donating our year-end draw prizes to thank participants who responded each month in 2000. (See page 13 for names of prize winners.)
Surveillance at Work

Overview

The CPSP is designed to study rare childhood disorders (less than 1,000 cases per year) or rare complications of commoner diseases of such low frequency that data collection nationally is required to generate a sufficient number of cases to derive meaningful data. When the CPSP Steering Committee reviews new study proposals, preference is given to studies that have strong public health importance or could not be undertaken any other way. All studies must conform to high standards of scientific rigour and practicality.

Upon initiation of a new study, program participants receive a summary of the protocol, including the case definition and a brief description of the condition. In addition to providing a uniform basis for reporting, this approach serves to educate and increase awareness of unusual or rare conditions.

The CPSP uses a two-tiered reporting process to ascertain and investigate cases: an initial ‘check-off’ form and a detailed reporting form. The full process is summarized in Figure 1.

Initial reporting

The initial reporting form, listing the conditions currently under surveillance, is mailed monthly to practising Canadian paediatricians and relevant paediatric subspecialists and health-care providers. Respondents are asked to indicate, against each condition, the number of new cases seen in the last month, including ‘nil’ reports. A ‘nil’ report is very important in active surveillance because the CPSP cannot simply assume that no reply means no cases.

Participants report all cases meeting the case definitions, including suspect or probable cases where there is some doubt about reporting. This sometimes leads to duplicate reports but avoids missed cases. Duplicate cases are identified during case follow-up.

Case ascertainment is monitored and verified by investigating duplicate reports and comparing data with the following programs or centres:

- Canadian Association of Paediatric Health Centres/Canadian Paediatric Decision Support Network
- IMPACT (Immunization Monitoring Program ACTive) centres
- Notifiable Diseases Reporting System, Centre for Infectious Disease Prevention and Control, Health Canada
- CJD-Surveillance System Canada
- Canadian Institute for Health Information

Respondents who do not reply every month receive quarterly reminders. As well, information including the monthly compliance rates and the number of
cases reported is mailed quarterly to all participants to keep them informed of progress.

The CPSP has a goal of over 90% response for case ascertainment. It is a continual challenge to attain such a high rate of response. Though some of the provincial response rates are climbing (see Table 1), the overall Canadian average has decreased in the last few years. One possible reason for this phenomenon is that the workload in the paediatric health-care system is straining the workplace. Are participants shying away from reporting cases because they know they will be asked to complete a detailed questionnaire? The CPSP tries to keep a fine balance between developing easy-to-complete forms that require the minimum amount of information and those that will maximize the information needed for analysis and meaningful interpretation.

Another reason may be that participants are still not reporting when they have not seen a case or they think their case is a duplicate that has been reported by another participant. The necessity for ‘nil’ reporting cannot be overly stressed. Also, duplicate reporting is important to ensure case ascertainment. Last year, two cases of congenital rubella syndrome were reported, one through the CPSP and the other through the Notifiable Diseases Reporting System; both should have been reported through the CPSP. Participants should be aware that, in order to keep the workload to a minimum, only one participant will receive a detailed questionnaire when duplicate cases are reported.

It is also interesting to note that the number of participants has increased each year as new certificants and study-related subspecialists are included in the program. The CPSP seeks to ensure that new participants are adequately educated regarding the importance of their participation. It is unknown at this time which of these possibilities, if any, has had an impact on the CPSP initial reporting rates by province/territory (%)

<table>
<thead>
<tr>
<th>Province/territory</th>
<th>1996</th>
<th>1997</th>
<th>1998</th>
<th>1999</th>
<th>2000</th>
<th>2001</th>
<th>Current number of participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alberta</td>
<td>79</td>
<td>91</td>
<td>93</td>
<td>88</td>
<td>89</td>
<td>88</td>
<td>227</td>
</tr>
<tr>
<td>British Columbia</td>
<td>74</td>
<td>83</td>
<td>84</td>
<td>81</td>
<td>81</td>
<td>77</td>
<td>245</td>
</tr>
<tr>
<td>Manitoba</td>
<td>81</td>
<td>90</td>
<td>90</td>
<td>86</td>
<td>85</td>
<td>86</td>
<td>117</td>
</tr>
<tr>
<td>New Brunswick</td>
<td>67</td>
<td>76</td>
<td>79</td>
<td>74</td>
<td>81</td>
<td>84</td>
<td>29</td>
</tr>
<tr>
<td>Newfoundland</td>
<td>67</td>
<td>74</td>
<td>80</td>
<td>73</td>
<td>78</td>
<td>82</td>
<td>42</td>
</tr>
<tr>
<td>Northwest Territories &amp; Nunavut</td>
<td>96</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>3</td>
</tr>
<tr>
<td>Nova Scotia</td>
<td>79</td>
<td>84</td>
<td>79</td>
<td>88</td>
<td>89</td>
<td>90</td>
<td>78</td>
</tr>
<tr>
<td>Ontario</td>
<td>74</td>
<td>81</td>
<td>86</td>
<td>84</td>
<td>82</td>
<td>82</td>
<td>913</td>
</tr>
<tr>
<td>Prince Edward Island</td>
<td>79</td>
<td>73</td>
<td>85</td>
<td>86</td>
<td>96</td>
<td>91</td>
<td>7</td>
</tr>
<tr>
<td>Quebec</td>
<td>75</td>
<td>80</td>
<td>83</td>
<td>81</td>
<td>80</td>
<td>78</td>
<td>628</td>
</tr>
<tr>
<td>Saskatchewan</td>
<td>61</td>
<td>75</td>
<td>74</td>
<td>67</td>
<td>68</td>
<td>61</td>
<td>47</td>
</tr>
<tr>
<td>Yukon</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>1</td>
</tr>
<tr>
<td><strong>Canadian average</strong></td>
<td><strong>76</strong></td>
<td><strong>82</strong></td>
<td><strong>86</strong></td>
<td><strong>83</strong></td>
<td><strong>82</strong></td>
<td><strong>81</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Total number of participants</strong></td>
<td><strong>2,071</strong></td>
<td><strong>1,978</strong></td>
<td><strong>2,126</strong></td>
<td><strong>2,216</strong></td>
<td><strong>2,296</strong></td>
<td><strong>2,337</strong></td>
<td><strong>2,337</strong></td>
</tr>
</tbody>
</table>
response rates. The Steering Committee, however, is concerned and committed to identifying the reasons for the decrease and ways to improve not only provincial but Canadian response rates.

To thank participants for their continued support, the program holds a year-end draw. In March 2001, participants who responded each month in 2000 were entered in a draw for a complementary dinner for two (maximum $100) at a restaurant of their choice. The winners were: Dr. Donald Levasseur (Edmundston, N.B.); Dr. Chor-Kei Chan (Victoria, B.C.) and Dr. Deborah Peabody (Portage La Prairie, Man.).

Follow-up and confirmation of case reports
The CPSP assures the confidentiality of all information provided to the program. Only non-nominal patient information, such as the date of birth, sex of the child and comments on the condition, is requested for each reported case. This information is used to identify duplicates and is entered, as a reminder, on a detailed reporting form, which is sent to the original respondent to request case-specific information. Once the detailed report is returned to the CPSP, it is forwarded to the investigator for analysis. The investigator is responsible for contacting the respondent if further information is required. The CPSP is encouraged by the high response rate for detailed questionnaires (Table 2).

One-time survey questions
The CPSP is now available as an inexpensive tool to survey participants on a one-time-basis in order to identify the prevalence of a problem or to answer a specific question. Once approved by the CPSP Steering Committee, the one-time survey question is sent to all participants with a monthly initial reporting form. Results are compiled and forwarded to the investigator. A one-time survey question concerning baby walkers was approved in 2001 for early 2002.

<table>
<thead>
<tr>
<th>TABLE 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CPSP 2001 response rates</strong></td>
</tr>
<tr>
<td><strong>Studies/conditions</strong></td>
</tr>
<tr>
<td>Acute flaccid paralysis</td>
</tr>
<tr>
<td>Anaphylaxis</td>
</tr>
<tr>
<td>Cerebral edema in diabetic ketoacidosis</td>
</tr>
<tr>
<td>CHARGE association/syndrome</td>
</tr>
<tr>
<td>Incidence (new cases)</td>
</tr>
<tr>
<td>Prevalence (old cases)</td>
</tr>
<tr>
<td>Congenital rubella syndrome</td>
</tr>
<tr>
<td>Hemolytic uremic syndrome</td>
</tr>
<tr>
<td>Hepatitis C virus infection</td>
</tr>
<tr>
<td>Necrotizing fasciitis</td>
</tr>
<tr>
<td>Neonatal herpes simplex virus infection</td>
</tr>
<tr>
<td>Neonatal liver failure/perinatal hemochromatosis</td>
</tr>
<tr>
<td>Progressive intellectual and neurological deterioration</td>
</tr>
<tr>
<td>Smith-Lemli-Opitz syndrome</td>
</tr>
<tr>
<td><strong>Total all studies</strong></td>
</tr>
</tbody>
</table>
TABLE 3

Criteria considered for inclusion of studies

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rarity</td>
<td>Disorders of such low incidence or prevalence that national ascertainment of cases is needed (less than 1,000 cases a year).</td>
</tr>
<tr>
<td>Public health importance</td>
<td>Clearly addressing a public or paediatric health issue.</td>
</tr>
<tr>
<td>Scientific importance</td>
<td>Demonstrated scientific interest and importance.</td>
</tr>
<tr>
<td>Uniqueness</td>
<td>Proposal must demonstrate a clear need for data on a condition or disorder for which there is only limited information and for which surveillance is the most appropriate means of collecting the data.</td>
</tr>
<tr>
<td>Quality of proposal</td>
<td>Proposal must state clear and achievable objectives, practicability, patient confidentiality, adequate resources, clear questionnaire and method of evaluation.</td>
</tr>
<tr>
<td>Workload of paediatricians</td>
<td>Steering Committee must be convinced that reporting will not make excessive additional demands on the workload of paediatricians.</td>
</tr>
</tbody>
</table>

Priority will be given to diseases that are not currently notifiable or, if notifiable, have sufficient indication of under-notification. Investigators are expected to demonstrate that potential funding is available.

Investigators’ corner

The CPSP can offer investigators the use of a timely, active surveillance system to increase awareness of rare paediatric conditions among the health-care community. It is a very inexpensive means of identifying and obtaining data on rare diseases and conditions from approximately 2,300 participants. The program is committed to a high case ascertainment rate of over 90% and boasts a high response rate on detailed reports (Table 2), due to follow-up reminders to participants who have not responded. The CPSP offers an opportunity for international collaboration with other paediatric surveillance units worldwide and a chance to make a difference in the health and well-being of Canadian children and youth.

Individual researchers are encouraged to submit proposals for new studies once they have reviewed the Criteria considered for inclusion of studies (Table 3) and the Format for submission (Table 4). The Steering Committee reviews submissions at its spring and fall meetings, giving preference to studies that have either strong public health importance or could not be undertaken any other way. Studies must receive ethical approval and have funding in place before final acceptance to the program.

As previously mentioned in the Overview section, the CPSP is available to investigators as an inexpensive tool to survey participants on a one-time basis in order to identify the prevalence of a problem or to answer a specific question.

TABLE 4

Format for submission

Proposals for new studies should include:
- name of principal author
- brief abstract of proposal
- proposed starting date
- proposed duration
- question(s) to be addressed by study
- statement of justification, including how the information could be used
- case definition
- expected number of cases
- availability of ethical approval (state source of approval)
- funding arrangements
- identification of projected date for completion of analysis and submission for publication
## Studies timeline

<table>
<thead>
<tr>
<th>Studies</th>
<th>Start date</th>
<th>End date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group B strep</td>
<td>January 1996</td>
<td>December 1996</td>
</tr>
<tr>
<td>Neural tube defects</td>
<td>January 1997</td>
<td>December 1998</td>
</tr>
<tr>
<td>Creutzfeldt-Jakob disease</td>
<td>January 1997</td>
<td>June 1999</td>
</tr>
<tr>
<td>Subacute sclerosing panencephalitis</td>
<td>January 1997</td>
<td>December 2000</td>
</tr>
<tr>
<td>Cerebral edema in diabetic ketoacidosis</td>
<td>July 1999</td>
<td>June 2001</td>
</tr>
<tr>
<td>Progressive intellectual and neurological deterioration</td>
<td>July 1999</td>
<td>June 2001</td>
</tr>
<tr>
<td>Anaphylaxis</td>
<td>January 2000</td>
<td>June 2001</td>
</tr>
<tr>
<td>Hemolytic uremic syndrome</td>
<td>April 2000</td>
<td>March 2002</td>
</tr>
<tr>
<td>Smith-Lemli-Opitz syndrome</td>
<td>January 2000</td>
<td>December 2002</td>
</tr>
<tr>
<td>Hepatitis C virus infection</td>
<td>February 2001</td>
<td>January 2003</td>
</tr>
<tr>
<td>CHARGE association/syndrome</td>
<td>September 2001</td>
<td>August 2003</td>
</tr>
<tr>
<td>Necrotizing fasciitis</td>
<td>September 2001</td>
<td>August 2003</td>
</tr>
<tr>
<td>Neonatal herpes simplex virus infection</td>
<td>October 2000</td>
<td>September 2003</td>
</tr>
<tr>
<td>Neonatal liver failure/perinatal hemochromatosis</td>
<td>February 2001</td>
<td>January 2004</td>
</tr>
<tr>
<td>Acute flaccid paralysis</td>
<td>January 1996</td>
<td>December 2004</td>
</tr>
<tr>
<td>Congenital rubella syndrome</td>
<td>January 1996</td>
<td>December 2004</td>
</tr>
</tbody>
</table>
Surveillance Studies in 2001

Acute flaccid paralysis

**Highlights**
- No wild polio cases have been reported in Canada since 1988, although importations of wild virus (without symptomatic disease) have been documented as recently as 1996.
- Guillain-Barré syndrome accounts for at least 76.9% of confirmed AFP cases.
- Polio viral stool cultures are still essential.

Canada continues its contribution to global polio surveillance.

**Background**
The elimination of indigenous wild poliovirus transmission in Canada, and the rest of the American region, was certified in September 1994. However, until global polio eradication is attained, there remains an ongoing risk of wild poliovirus importation from polio-endemic regions to Canada. Consequently, active surveillance of acute flaccid paralysis (AFP) in children less than 15 years old is used to monitor potential cases of paralytic poliomyelitis. Based on an estimated background annual incidence of one case per 100,000 in a population less than 15 years of age in the absence of wild poliovirus transmission, the estimated minimum number of AFP cases in Canada is 58 per year. AFP surveillance in Canada was initiated in 1991 through the IMPACT (Immunization Monitoring Program ACTive) network of paediatric tertiary care centres and, since 1996, has been implemented through the CPSP. This report presents the results of AFP surveillance in 2001 and compares them to those from previous years.

**Objective**
The objective of AFP surveillance is to identify AFP cases (including Guillain-Barré syndrome [GBS]) in children less than 15 years of age to rule out paralytic poliomyelitis and thereby monitor the polio-free status of Canada.

**Case definition**
Acute onset of focal weakness or paralysis characterized as flaccid (reduced tone) without other obvious cause (e.g., trauma) in children less than 15 years of age. Transient weakness (e.g., post-ictal weakness) should not be reported.

**Duration**
January 1996 to December 2004

**Results and discussion**
In 2001, the CPSP received 86 initial AFP reports, of which 34 (39.5%) were discarded. They included 28 duplicate reports, four cases that did not meet the AFP surveillance case definition, and two pending.

Fifty-two confirmed cases represent a rate of 0.9% per 100,000 which is slightly below the minimum estimated background rate of one case per 100,000 population less than 15 years of age, or 58 cases. With the anticipated ‘late reports’ for the current year, the final number is likely to get closer to the targeted rate.

The cases ranged in age from seven months to 14.9 years (median 6.9, mean 7.4 years). Table 6 shows the age distribution of AFP cases reported from 1996 to 2001. Overall, the age distribution is similar throughout the reporting period. Both sexes were almost equally distributed (males accounted for 52%).

Polio vaccination status: In 2001, only 27 cases (52%) had documentation for having received any polio vaccination; for the remaining 25 cases, no polio
vaccine-specific information was available on the case report form. Of these 27 cases assessed, 25 (93%) had received age-appropriate polio immunization. One case had no vaccination at all. Although most of these children are likely to be vaccinated against routine vaccine preventable diseases, documentation of vaccination history on the surveillance form was absent or left blank due to lack of follow-up or difficulty in getting the information from primary health-care providers.

Virological investigation for polio or other enteroviruses: A total of 25 (48%) cases had stool examination; virology was not done or the status was unknown for 27 (52%) cases. However, adequate stool investigation for the isolation of poliovirus or non-polio enteroviruses (i.e., stool specimen collected within two weeks of the onset of paralysis) was reported only for 21 (40% of 52) cases (for four additional cases, although stool specimens were collected, it was after two weeks of onset of paralysis); none were positive for polioviruses; one each was characterized as 'enterovirus' and 'adenovirus'. None of the 15 throat and/or 29 cerebrospinal fluid specimens collected for viral isolation was positive for poliovirus.

Neurological investigations consisted of at least one of the following: CSF examination, nerve conduction studies, electromyography, MRI or CT scan; abnormal findings compatible with the neurological diagnosis were reported for one or more of the tests done. CSF study was done for 38 cases (73%); 31 (82%) showed some abnormality. MRI or CT scanning was done for 36 cases (69%); eight of the 36 (22%) showed some abnormality. Electromyography and/or nerve conduction studies were done for 38 cases; 30 (79%) of these cases had abnormal findings.

The final neurological diagnosis was reported as Guillain-Barré syndrome in 36 cases (69.2%), Miller-Fisher variant in four (7.7%) and transverse myelitis in eight (15.4%) (Table 7). The remaining four diagnoses included viral areflexic myositis (isolated influenza virus-B and Mycoplasma pneumoniae from throat swab) (1), acute ataxia (1), polyradiculoneuritis (1), and myasthenia gravis (1).

Forty-seven of the 52 cases (90.4%) required hospitalization for periods ranging from one to over 49 days (mean of 9.5 days); two cases were hospitalized for 30 days or longer. Of the total of 52 cases, three (5.8%) were fully recovered at 60 days after the onset of paralysis, 39 (75%) had recovered partially with residual weakness, and for the remaining 10 cases (19.2%), recovery status was unknown at 60 days after the onset of paralysis.

None of the clinical specimens tested, i.e., stool, nasopharyngeal or cerebrospinal fluids, were positive for polio virus infection.

Although duplicate reporting remains relatively high, in many instances duplicate reports provided additional information not included in the ‘primary’ report, thereby proving to be very useful. All participating paediatricians, paediatric neurologists and IMPACT monitors are therefore still encouraged to submit detailed reporting forms even when they suspect a case to be a potential duplicate, unless there is a clear indication that the information reported would be the same (e.g., where there is a designated reporter among a group of paediatricians in the same practice).

Conclusions

The 52 AFP cases identified to date for 2001 indicate that the surveillance system continues to be sensitive enough to detect almost all expected cases in Canada, according to the World Health Organization (WHO) criteria, for the non-polio AFP cases in the targeted population (children under 15 years) in the absence of circulation of wild poliovirus. For the corresponding period for 2000, a total of 57 cases
were reported initially, but the final number has now increased to 61 with the inclusion of four additional cases reported in 2001.

It is encouraging to note that the AFP reporting rate has improved since the introduction of paediatrician-based reporting through the CPSP from 0.5 per 100,000 children less than 15 years in 1996 (30 cases) to 1.04 per 100,000 in 2000 (61 cases) and 0.9 per 100,000 in 2001 (52 cases). It also supports previous observations that the expansion of AFP surveillance to the CPSP has improved the completeness of surveillance by ensuring that AFP cases seen at non-tertiary hospitals are reported in addition to those cases admitted to paediatric tertiary care hospitals and reported through IMPACT.

A major area in which the AFP surveillance could be improved is the performance of polio-specific investigations and timely reporting of results. The

### TABLE 6

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0 – 1</td>
<td>2 (6.7)</td>
<td>0</td>
<td>2 (4.6)</td>
<td>3 (4.9)</td>
<td>2 (3.3)</td>
<td>8 (15.4)</td>
</tr>
<tr>
<td>2 – 5</td>
<td>11 (36.7)</td>
<td>13 (37.1)</td>
<td>15 (34.9)</td>
<td>18 (29.5)</td>
<td>24 (39.3)</td>
<td>17 (32.7)</td>
</tr>
<tr>
<td>6 – 10</td>
<td>9 (30.0)</td>
<td>12 (34.3)</td>
<td>18 (41.9)</td>
<td>23 (37.7)</td>
<td>22 (36.1)</td>
<td>13 (25.0)</td>
</tr>
<tr>
<td>11 – &lt;15</td>
<td>8 (26.6)</td>
<td>10 (28.6)</td>
<td>8 (18.6)</td>
<td>17 (27.9)</td>
<td>13 (21.3)</td>
<td>14 (26.9)</td>
</tr>
<tr>
<td>Total</td>
<td>30 (100)</td>
<td>35 (100)</td>
<td>43 (100)</td>
<td>61 (100)</td>
<td>61 (100)</td>
<td>52 (100)</td>
</tr>
</tbody>
</table>

* Includes four delayed reports not included in the CPSP 2000 Results

### TABLE 7

<table>
<thead>
<tr>
<th>Final Diagnosis</th>
<th>Number of cases (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polio</td>
<td>0</td>
</tr>
<tr>
<td>Guillain-Barré syndrome</td>
<td>21 (70.0)</td>
</tr>
<tr>
<td>Transverse myelitis</td>
<td>6 (20.0)</td>
</tr>
<tr>
<td>Encephalitis/encephalomyelitis/encephalopathy</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>Myelopathy</td>
<td>—</td>
</tr>
<tr>
<td>Radiculopathy/radiculoneuritis</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>Plexitis/lumbosacral plexitis</td>
<td>—</td>
</tr>
<tr>
<td>Brachial neuritis</td>
<td>—</td>
</tr>
<tr>
<td>Rhombomylitis</td>
<td>—</td>
</tr>
<tr>
<td>Other</td>
<td>—</td>
</tr>
<tr>
<td>Not specified/undetermined diagnosis or etiology</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>Total</td>
<td>30 (100)</td>
</tr>
</tbody>
</table>

* Includes four delayed reports not included in the CPSP 2000 Results
proportion of cases where polio-specific laboratory investigations were reported remained low in 2001; only 48% of cases had an adequate stool investigation during this period. Although this is, for the most part, an improvement over previous years (33% in 1996, 37% in 1997, only 25% in 1998, 42% in 1999, and 51% in 2000) the rate of adequate stool investigation remains significantly lower than the WHO target of 80%. While neurological investigations provide supporting evidence for the final diagnosis in the majority of reported AFP cases, polio-specific laboratory investigations remain vital for the evaluation of all cases, including those in which poliomyelitis is not being considered as a possible diagnosis. Negative results of appropriate polio-specific investigations are as important as a positive result would be in AFP case evaluations. The single most important laboratory investigation, recommended by the National Working Group on Polio Eradication to confirm or to rule out a diagnosis of paralytic poliomyelitis, is a stool specimen collected within two weeks of onset of paralysis for isolation of wild or vaccine strain poliovirus; specimens may be collected up to six weeks after the onset of paralysis, although after two weeks, the sensitivity of virus isolation decreases. The examination of paired serum samples for evidence of a fourfold or greater rise in poliovirus antibody titre in paired sera and/or the presence of poliovirus-specific IgM antibody in a single serological specimen further enhance the evaluation of cases.

**Principal investigator**
Paul Varughese, DVM, MSc, Division of Immunization and Respiratory Diseases, Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada, Tunney’s Pasture PL 0603E1, Ottawa ON K1A 0L2; tel.: 613-957-1344; fax: 613-998-6413; e-mail: paul_varughese@hc-sc.gc.ca

---

**Anaphylaxis**

**Highlights**

- Anaphylaxis affects the entire paediatric population from age one month to 17 years.
- Thirty-one percent of anaphylaxis episodes occurred after the first known exposure to the trigger.
- Eighty-one percent of anaphylaxis episodes were triggered by foods, especially peanuts.
- Injection of epinephrine, the first-aid treatment of choice in anaphylaxis, was often delayed or omitted.

**Background**

In the paediatric population, until recently, anaphylaxis from all triggers was considered to be relatively rare, although other atopic disorders such as asthma and allergic rhinitis had reached epidemic proportions. By using active, real-time surveillance as a novel approach to studying anaphylaxis, the study aimed, through the CPSP, to provide a new perspective on this potentially fatal disorder in the paediatric population.

**Objective**

To define the picture of anaphylaxis in Canadian infants, children, and teens with regard to:

---

**The clinical picture of anaphylaxis in Canadian infants, children and teens has been defined, thanks to the information provided by 130 reporting physicians in the CPSP.**

Dr. Estelle Simons
Case definition

A confirmed case is an infant or child 18 years or less with a severe allergic reaction to any stimulus having sudden onset and lasting less than 24 hours. One or more body systems may be involved and multiple symptoms such as hives, flushing, angioedema, stridor, wheezing, shortness of breath, vomiting, diarrhea or shock may be evident.

1) Provoking factors: foods, insect stings/bites, latex rubber, medications, exercise, cold, or other stimuli.

2) Symptoms: cutaneous, respiratory, gastrointestinal, cardiovascular and/or central nervous system involvement.

3) Documentation:
   - at the time of the episode: clinical history, physical examination, and serum tryptase levels, if available;
   - weeks or months after the episode: skin tests for confirmation of allergy to the suspected trigger (food, insect sting/bite, latex rubber, or medication); tests for other provoking factors such as exercise.

Duration

January 2000 to June 2001

Results

During active surveillance from January 1, 2000 to June 30, 2001 inclusively, 98% of the 130 physicians who reported anaphylaxis cases to the CPSP voluntarily completed detailed case-specific questionnaires. Cases were discarded if they occurred before January 1, 2000, or after June 30, 2001, if they occurred in patients 18 years of age or older, or if they did not meet the case definition.

More than 700 episodes of anaphylaxis involving patients aged one month to 17 years were reported, including one fatality in a food-allergic teen. Sixty percent of all anaphylaxis episodes occurred in males; 60% of all episodes occurred in children less than six years of age; 64% of all episodes occurred in the child’s home, and a parent was present during 75% of all episodes. Thirty-one percent of episodes occurred following a child’s first known exposure to the trigger; 25% of episodes occurred in children who had a history of a previous reaction to the trigger.

Eighty-one percent of all episodes were triggered by foods, most commonly peanuts, tree nuts, cow’s milk, eggs, fish/shellfish, and fruits/vegetables. Non-food triggers such as medications (8%), insect stings (4%), latex rubber (2%), exercise (2%), immunotherapy (2%), and other (1%) were also reported.

Symptoms and signs involved the skin in 91% of episodes, and other systems as follows: respiratory (69%), gastrointestinal (43%), cardiovascular (8%) and central nervous system (3%). Signs and symptoms usually occurred in more than one body system concurrently, and multiple symptoms and signs often occurred within the same body system. Skin symptoms and signs included urticaria (64%), angioedema/swelling (59%), flushing (23%), and itch only (5%). Respiratory symptoms and signs included dyspnea (36%), wheeze (30%), cough (27%), hoarseness/stridor (13%), choking (12%), and chest tightness (6%). Nasal symptoms occurred in 8% and eye symptoms in 5% of the episodes. Gastrointestinal symptoms and signs included vomiting (34%), nausea (6%), abdominal cramps (6%), dysphagia (5%) and diarrhea (4%).
Epinephrine was injected in 32% of episodes; however, it was not available in 29% and was available but not given in 12%. An H1-antihistamine, usually oral diphenhydramine, was administered in 54% of the episodes. Corticosteroid treatment was given in 14% of episodes.

**Discussion**

Not only is this the first prospective, real-time, study of anaphylaxis using a national reporting network, but it is also the largest “all triggers” anaphylaxis study in patients of any age reported to date. The results summarize the national experience with anaphylaxis in an entire paediatric population over 18 consecutive months.

Anaphylaxis affects the entire paediatric population from the age of one month to 17 years. It predominantly occurs in young children, and is more likely to occur in boys than in girls. New findings in this study were that a parent was present during 75% of the episodes, and that in 31% of the episodes, no known previous exposures to the trigger had occurred. The symptoms and signs of anaphylaxis in infants and very young children are described clearly for the first time.

Despite the large number of anaphylaxis episodes reported, the study likely underestimated the true occurrence rate of anaphylaxis in the paediatric population. For example, episodes in which the child’s caregiver or physician failed to recognize anaphylaxis as such would not have been included. Adolescents, who are less likely than younger children to be in regular contact with a paediatrician, may also have been under-represented. Episodes, in which a child was diagnosed and treated for anaphylaxis by a family physician only, and not by a specialist such as a paediatrician or an allergist, would not have been captured, as family physicians do not report to the CPSP. Moreover, some patients with anaphylaxis, seen by CPSP physicians, may not have been reported due to the workload involved.

Several opportunities to educate physicians and the public about anaphylaxis in children were identified in the CPSP anaphylaxis study. The three most important messages are as follows: 1) Anaphylaxis triggers, identified on the basis of the history, must be confirmed by appropriate allergy and other tests so the trigger can be avoided. 2) Failure to recognize anaphylaxis promptly leads to delay in epinephrine injection, the first-aid treatment of choice, and/or to inappropriate treatment. 3) Most deaths from anaphylaxis are preventable, with confirmation of the trigger factor, long-term avoidance of the trigger, and prompt first-aid treatment with epinephrine.

**Conclusions**

Using active surveillance, a novel method of data collection involving real-time physician reporting, it was found that anaphylaxis is not a rare disorder in the Canadian paediatric population. It was most commonly reported in young children and in boys. Food was the most common trigger factor. Non-food triggers included medications and biologicals, insect stings, latex rubber, and exercise. Epinephrine injection was under-utilized in first-aid treatment.

**Principal investigator**

F Estelle R. Simons, MD, Section of Allergy & Clinical Immunology, Department of Pediatrics & Child Health, University of Manitoba, Room AE101, 820 Sherbrook St, Winnipeg MB R3A 1R9; tel.: 204-787-2440; fax: 204-787-5040; e-mail: lmcniven@hsc.mb.ca

**Co-investigators**

Zave Chad, MD, Ottawa, ON
Milton Gold, MD, University of Toronto
Cerebral edema in diabetic ketoacidosis

Highlights
- Four out of 16 children died of CE-DKA; this phenomenon is comparable to other reported studies.
- Only one in 12 of the surviving children had residual neurologic sequelae.
- It appears, upon preliminary analysis, that the risk factors for CE-DKA are new onset diabetes, high initial urea and low initial serum bicarbonate.
- No association was found with any treatment factors in the preliminary analysis.

Background
Diabetic ketoacidosis (DKA) is a common complication of diabetes, occurring in up to 25 to 40% at diagnosis of diabetes and in approximately 5% of patients per year with established diabetes. Previous reports have found that one to three percent of cases of DKA are complicated by cerebral edema (CE) which is associated with significant morbidity (21 to 35%) and mortality (21 to 24%). A recent population study through the British Paediatric Surveillance Unit showed the calculated risk of developing cerebral edema was 6.8 per 1,000 episodes of DKA. The risk factors for the development of CE-DKA remain controversial. Those implicated have included features at presentation (age under five years, new onset diabetes, long duration of symptoms, high initial urea, low initial pCO₂) and treatment factors (too rapid or inadequate fluid administration, use of hypotonic fluids, failure of serum sodium to rise during treatment).

Objectives
1) To determine the incidence of cerebral edema in association with DKA in Canadian children.
2) To determine outcome of cerebral edema in association with DKA.
3) To identify risk factors for cerebral edema in association with DKA.

Case definitions
1) Children up to their 16th birthday.
2) Sudden or unexpected deterioration in level of consciousness in a child or adolescent with DKA (pH < 7.35 and/or bicarbonate < 18 mmol/L in association with diabetes and ketonuria).
3) Any death in a child or adolescent with type 1 or type 2 diabetes, either during or unrelated to an episode of DKA.

Cases with profound depression of level of consciousness at presentation were also considered. A retrospective search of medical records, in all reporting centres, from 1995 to 1999 identified additional cases. Two unmatched controls/cases were reviewed.

Duration
July 1999 to June 2001
Results

FIGURE 2

Summary of reports and identification of cases for case control study of risk factors for CE-DKA

TABLE 8

Demographic characteristics and initial laboratory values of cases and controls – Interim analysis results

<table>
<thead>
<tr>
<th></th>
<th>Cerebral edema (N=16)</th>
<th>Controls (N=40)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)†</td>
<td>9.6 ± 4.1</td>
<td>9.4 ± 4.3</td>
<td>0.36</td>
</tr>
<tr>
<td>Male sex (%)†</td>
<td>6 (37.5)</td>
<td>20 (50)</td>
<td>0.16</td>
</tr>
<tr>
<td>Newly diagnosed (%)†</td>
<td>13 (81.3)</td>
<td>19 (47.5)</td>
<td>0.008</td>
</tr>
<tr>
<td>Duration of vomiting† (days)</td>
<td>1.4 ± 1.6</td>
<td>1.1 ± 1.2</td>
<td>0.09</td>
</tr>
<tr>
<td>Glucose‡</td>
<td>55.5 ± 29.8</td>
<td>33.2 ± 14.9</td>
<td>0.02</td>
</tr>
<tr>
<td>Urea‡</td>
<td>13.5 ± 5.4</td>
<td>6.6 ± 13.5</td>
<td>0.003</td>
</tr>
<tr>
<td>pCO2‡</td>
<td>19.9 ± 9.7</td>
<td>25.2 ± 11.3</td>
<td>0.21</td>
</tr>
<tr>
<td>HCO3‡</td>
<td>5.9 ± 3.0</td>
<td>10.2 ± 5.5</td>
<td>0.002</td>
</tr>
<tr>
<td>Corrected Na‡</td>
<td>151.8 ± 13.7</td>
<td>147.1 ± 8.3</td>
<td>0.22</td>
</tr>
</tbody>
</table>

* This is an interim analysis. Consequently, chi ratio significance was set at a p-value of <0.01.
† Analysis of demographic variables by logistic regression analysis.
‡ Analysis of initial laboratory data by chi ratio with Bonferroni adjustment.
Objective-specific results
1) Incidence of CE-DKA: Incidence determination will follow once national data on DKA is available.

2) Outcome: The mortality rate of four in 16 cases is in keeping with other reports. However, only one in 12 of the survivors had residual neurological deficits, which is lower than previously reported. Fluid use prior to CE was conservative in this study (6.5 cc/kg/hr in cases and 3.6 cc/kg/hr in controls). A previous study by Harris et al in 1990 found that rates of CE-DKA did not change with reduced fluids, but outcome improved.

3) See Table 8 and Figure 3 for preliminary analysis results of risk factors for CE-DKA in this cohort.

Conclusions
• Risk factors for cerebral edema in DKA in this cohort include:
  • new onset diabetes
  • low initial bicarbonate
  • high initial urea

• No association was found with previously reported risk factors including:
  • young age
  • long duration of symptoms
  • low initial pCO₂
  • rapid administration of hypotonic fluids

• The observed mortality rate of four out of 16 is similar to previous reports. However, outcome for survivors was better than previously reported (only one child in 12 had residual neurologic sequelae).

• This is a preliminary analysis. Data collection is pending on six prospective and an undetermined number of retrospective cases.

Principal investigator
Sarah Muirhead, MD, University of Ottawa, Division of Endocrinology and Metabolism, Children’s Hospital of Eastern Ontario, 401 Smyth Rd, Ottawa ON K1H 8L1; tel.: 613-737-2434; fax: 613-738-4236; e-mail: muirhead@cheo.on.ca

Co-investigators
Elizabeth Cummings, MD, Dalhousie University
Denis Daneman, MD, University of Toronto
CHARGE association/syndrome

Highlights

• In the first four months of the study, 50 confirmed CHARGE association/syndrome cases were reported.
• The incidence of CHARGE association/syndrome varies between province/region from zero to eight per 100,000 live births.
• The mean age at diagnosis of CHARGE association/syndrome has decreased dramatically over the last 24 years from 11 years of age to 1.5 months.

Background

CHARGE association/syndrome (CHARGE A/S) is a constellation of a number of congenital anomalies that was first given the acronym CHARGE (Coloboma, Heart Defect, Choanal Atresia, Retarded Growth and Development, Genital Hypoplasia, Ear Anomalies/Deafness) in 1981. Over the past 15 years, the specificity of this pattern of malformations has reached the level that many clinicians now consider it to be a discrete recognizable syndrome (Graham JM. Am J Med Gen 2001;99:120-3). With increasing expertise, it became clear that the criteria originally proposed needed further refinement. The revised consensus diagnostic criteria by Blake et al, (Clin Pediatr1998;37:159-74) incorporating both major and minor features for CHARGE A/S have been documented to enhance clinical diagnosis and facilitate research efforts. These criteria consist of four major characteristics: coloboma, choanal atresia, specific ear anomalies, cranial nerve dysfunction (facial palsy, vestibular dysfunction, and swallowing difficulties) and seven minor criteria: heart defect, orofacial cleft, genital hypoplasia, growth deficiency, developmental delay, tracheoesophageal fistula and a distinct facial appearance. The diagnosis is firmly established when all four major or three major and three minor criteria are present. Some of the criteria are difficult to detect in infants, and as the major characteristics are rare in other conditions, the CHARGE A/S diagnosis needs to be considered in any individual who has one or two major criteria and several minor characteristics. To define CHARGE A/S in these individuals, a cranial CT scan may show classical anomalies of the temporal bones, choanae or brain. High resolution chromosome studies, the Fluorescent In Situ Hybridisation (FISH) for 22q11 deletion and recently subtelomeric testing (rearrangements at the end of the chromosomes) may help confirm a case.

The true incidence of CHARGE A/S is not known, therefore the purpose of this study is to determine the incidence and prevalence of CHARGE A/S in Canada. Using the Maritime data (estimated incidence of eight per 100,000), it is expected that 30 new cases per year will be diagnosed in Canada. As CHARGE A/S presents with a wide spectrum of clinical severity, mildly affected patients may also be diagnosed and can be followed prospectively. The review article, entitled “Charge Association: An Update and Review for the Primary Paediatrician” (Clin Pediatr 1998;37:159-74), summarizes our current understanding of the management of this complex and chronic multiple congenital anomaly, giving physicians a guide to the management of CHARGE A/S.
To date, no predictive factors regarding the developmental prognosis of CHARGE A/S infants have been identified. Because of their multiple complex medical/surgical issues, many initial care providers overestimate the severity of developmental and behavioural disability in the absence of reliable data. Only by careful prospective follow-up of a population of CHARGE A/S infants that have been ascertained using the CPSP can their developmental profile be defined and compared to the reported literature. An increase in paternal age of CHARGE A/S children has been recognized and needs to be confirmed.

**Objectives**

1) To determine the incidence and prevalence of CHARGE A/S in Canada by ascertaining all identified cases of CHARGE A/S (old and new).

2) To obtain demographic and medical information on patients with CHARGE A/S, and assemble a database to answer such research questions as: Do certain CHARGE A/S features predict mortality and morbidity? Is paternal age increased compared to the general population? Do renal anomalies occur more frequently in CHARGE A/S than has been documented in the literature?

3) To follow developmentally and behaviourally an identified group of CHARGE A/S infants who have been diagnosed at an early age and have obtained early intervention services. Will early recognition and treatment of these infants improve their clinical and behavioural well-being?

**Case definitions**

1) Infant/child/adult with all four major criteria.

2) Infant/child/adult with three major and three minor criteria.

3) Previously diagnosed child with CHARGE A/S that does not fit major or minor criteria, but has a combination of the above, plus some occasional findings: renal, hand, spine/limb, abdominal (hernia) anomalies.

**Major inclusion criteria**

1) Coloboma – of iris, retina, choroid, disc; microphthalmia

2) Choanal atresia – unilateral/bilateral, membranous/bony, stenosis/atroresia

3) Characteristic ear abnormalities – external ear (lop- or cup-shaped), middle ear (ossicular malformations, chronic serous otitis), mixed deafness, cochlear defects

4) Cranial nerve dysfunction – facial palsy (unilateral or bilateral), sensorineural deafness and/or swallowing problems

**Minor inclusion criteria**

1) Genital hypoplasia – males: micropenis, cryptorchidism; females: hypoplastic labia; both males and females: delayed, incomplete pubertal development

2) Developmental delay – delayed motor milestones, language delay, mental retardation

3) Cardiovascular malformations – all types, especially conotruncal defects (e.g., tetralogy of Fallot), AV canal defects, and aortic arch anomalies

4) Growth deficiencies – short stature, growth hormone deficiency

5) Orofacial cleft – cleft lip and/or palate

6) Tracheoesophageal (TE) fistula – tracheoesophageal defects of all types

7) Characteristic face – sloping forehead, flattened tip of nose

**Exclusion criteria**

Exclude other conditions such as velocardiofacial syndrome (VCS) and DiGeorge Sequence (DGS) using FISH test (Fluorescent In Situ Hybridisation) to exclude 22q11 deletion.

**Duration**

September 2001 to August 2003

**Results**

In the first four months of CHARGE A/S surveillance, there were 69 initial reports. Of these, 50 were
reported, 65% compared to 50-60%, and there were no females diagnosed with genital hypoplasia.

Frequencies are based on the number of confirmed cases of CHARGE A/S known to have the specific anomaly (N), compared to the number of cases reporting the presence or absence of the anomaly (responses).

Using the number of reported cases, an estimate of the incidence of CHARGE A/S in Canada and in each province was calculated, based on the number of CHARGE A/S individuals born between July 1, 1997 and June 30, 2001 (Table 10). The variation in the incidence of CHARGE A/S between provinces is compelling and is likely due to higher reporting rates in areas where there is a specific interest in CHARGE A/S. Therefore, the incidence of CHARGE A/S varies between provinces/regions from zero to eight per 100,000 live births.

Table 11 demonstrates a dramatic decrease in the mean age at diagnosis over the last 24 years from 11 years to 1.5 months. CHARGE A/S individuals born between 1997 and 2001 were diagnosed at 1.5 months, on average, with many diagnoses made in the neonatal period. Between 1992 and 1996,
children were, on average, 17 months at the time of diagnosis, while children born previous to 1992 were on average 11 years when they were first diagnosed with CHARGE A/S. This has huge implications for the developmental outcome of these children, since early intervention has been shown to be critical in children with sensory deficits. It will be interesting to follow this cohort of infants and young children who were diagnosed with CHARGE A/S as neonates and monitor their development.

The number of cases is based on the number of reported cases where the birth date falls between July 1, 1997 and June 30, 2001. The birth rates are based on figures from Statistics Canada for the period July 1, 2000 to June 30, 2001. The average age at diagnosis was determined for reported CHARGE A/S patients born within the time periods.

Etiological heterogeneity may be associated with variable expressivity. Twenty-five confirmed CHARGE A/S cases had normal FISH-22q11 deletion studies, 24 had no reported tests, and one report had 22q11 deletion (this case will require further clinical evaluation). Subtelomeric testing, which is becoming more widely available in Canada, is recommended as a second genetic screen. Identifying a more homogenous group of CHARGE A/S cases meeting the criteria that have been proposed as a recognizable syndrome (Graham, 2001) might be useful for genetic investigation.

### TABLE 11

<table>
<thead>
<tr>
<th>Number of cases</th>
<th>Mean age at diagnosis months (standard deviation)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>1997–2001</td>
<td>42</td>
<td>1.5 (±2.16)</td>
</tr>
<tr>
<td>1992–1996</td>
<td>7</td>
<td>17 (±23.25)</td>
</tr>
<tr>
<td>1978–1991</td>
<td>13</td>
<td>121 (±108)</td>
</tr>
</tbody>
</table>

### Conclusions

CHARGE A/S appears to be under-reported in many provinces. However, the average age at diagnosis has improved from several years to the first few months of life. Physicians are more aware of defects that may not be obvious at birth (hearing impairment, retinal coloboma, feeding difficulties, renal anomalies) and are able to recheck vision and hearing regularly. A temporal bone scan may confirm the diagnosis and should be part of the workup of any infant with suspected CHARGE A/S. While the FISH test proves valuable to exclude other diagnoses, subtelomeric testing is now recommended.

### Principal investigator

Kim Blake, MB, MRCP, Division of Medical Education, IWK Health Centre, Halifax NS B3J 3G9; tel.: 902-470-6499; fax: 902-470-7216; e-mail: kblake@is.dal.ca

### Co-investigators

John M. Graham, Jr, MD, Clinical Genetics and Dysmorphology, Cedars Sinai Medical Centre
Chitra Prasad, MD, Section of Genetics and Metabolism, University of Manitoba
Isabel M. Smith, PhD, Departments of Paediatrics and Psychology, Dalhousie University and IWK Health Centre

### CHARGE parents (for families of CHARGERS in Canada)

Debbie Cachia, tel.: 705-448-2894; e-mail: dcachia@sympatico.ca
Lisa Weir, e-mail: gweir@nbnet.nb.ca
Congenital rubella syndrome

Highlights
• In 2001, for the first time since national notification of CRS began in 1979, no congenital rubella syndrome was reported in Canada.
• From 1996 to 2001, zero to two newborns with CRS per year were identified through the surveillance systems in Canada (0 to 0.5 per 100,000 births).
• Standing orders for vaccination of all rubella susceptible women in the immediate postpartum period are essential.

Rubella and congenital rubella syndrome are contagious vaccine preventable diseases and remain a risk particularly in immigrant and unvaccinated populations. Continuous vigilance and total vaccine protection for all are to be maintained.

Dr. Paul Varughese

Background
In Canada, rubella immunization programs were introduced in the 1970s. However, the program strategies varied; some provinces initially opted for selective immunization of pre-adolescent females and others opted for immunization of all infants. By 1983, all provinces and territories across Canada had implemented routine measles-mumps-rubella combined vaccine (MMR) at 12 months. During 1996 and 1997, all provinces and territories introduced a routine second dose MMR or measles-rubella combined vaccine (MR) given at 18 months or four to six years. Some jurisdictions used MR vaccine for their second dose catch-up campaigns.

Since 1970 the incidence of rubella in Canada has declined markedly; fewer than 30 cases were reported annually in the past two years. During a national consensus conference in 1994, a goal of eliminating indigenous rubella infection during pregnancy by the year 2000 was established. In November 2001, a National Expert Working Group on Rubella recommended that all rubella infections be included for enhanced surveillance.

In Canada, passive reporting of congenital rubella syndrome (CRS) to the Notifiable Diseases Reporting System (NDRS) began in 1979. Active surveillance of CRS began in 1992 through a network of tertiary care paediatric hospitals (now representing more than 85% of paediatric tertiary care beds in Canada) participating in IMPACT (Immunization Monitoring Program ACTive).

Objectives
1) To estimate the incidence of congenital rubella syndrome and congenital rubella infection in Canada.
2) To obtain detailed epidemiological data, including maternal histories, on reported cases of congenital rubella syndrome and infection.

Case definitions
Confirmed case
Live birth
Two clinically compatible manifestations (any combination from Table 12, columns A and B) with laboratory confirmation of infection:
• isolation of rubella virus from an appropriate clinical specimen;
or
• detection of rubella-specific IgM in the absence of recent immunization with rubella-containing vaccine;
or
• rubella-specific IgG persisting at elevated levels for longer than would be expected from passive transfer of maternal antibody, or in the absence of recent immunization.

Stillbirth
Two clinically compatible manifestations with isolation of rubella virus from an appropriate clinical specimen.

Note: The following cannot be classified as a CRS case:
• rubella antibody titre absent in the infant;
or
• rubella antibody titre absent in the mother;
or
• significant rise in serum rubella IgG antibody levels by any standard serological assay;
• positive serologic test for rubella-specific IgM;
• clinical illness* in a person who is epidemiologically linked to a laboratory-confirmed case.

* Clinical illness is characterized by fever and rash, and at least one of the following: arthralgia/arthritis, lymphadenopathy, conjunctivitis. Up to 50% of rubella infections are reported to be subclinical.

Duration
January 1996 to December 2004

Results and discussion
In 2001, no cases of CRS were identified in Canada, by the Notifiable Diseases Reporting System or by the CPSP. The very low incidence of CRS and rubella infection suggest that Canada is getting closer to achieving the goal of eliminating indigenous rubella infection during pregnancy.

From January 1996 to December 2001, with active surveillance in place, seven new cases of newborns with CRS were reported in Canada (Table 13). Of those whose status was recorded, two were born to

### TABLE 12

**Congenital rubella syndrome: clinically compatible manifestations**

<table>
<thead>
<tr>
<th>Column A</th>
<th>Column B</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Cataracts or congenital glaucoma (either one or both count as one)</td>
<td>1. Purpura</td>
</tr>
<tr>
<td>2. Congenital heart defect</td>
<td>2. Hepatosplenomegaly</td>
</tr>
<tr>
<td></td>
<td>5. Mental retardation</td>
</tr>
<tr>
<td></td>
<td>6. Meningoencephalitis</td>
</tr>
<tr>
<td></td>
<td>7. Radiolucent bone disease</td>
</tr>
<tr>
<td></td>
<td>8. Developmental or late onset conditions, such as diabetes and progressive paraparesis, and any other conditions possibly caused by rubella virus</td>
</tr>
</tbody>
</table>
immigrant women, one to an aboriginal woman, and two to non-aboriginal women. These five cases illustrate the need for documentation of previously received rubella vaccination, of maternal immunity status, and postpartum rubella vaccine when indicated.

Conclusions
Health-care providers are requested to ensure that: 1) all patients receive their rubella vaccinations at the recommended ages and 2) all women without documented proof of rubella immunization receive the vaccine. Special attention should be given to the review of vaccination records of women from regions with poor vaccination coverage, including women in immigrant populations. Routine rubella antibody screening antenatally is central to the congenital rubella prevention strategy, and all women found to be susceptible should be vaccinated in the immediate postpartum period. A standing order for the vaccination of susceptible women before discharge from hospital is the most effective way to ensure that the opportunity is not missed.

The degree of under-diagnosis and under-reporting for congenital rubella infection (CRI), CRS with less severe manifestations and CRS with delayed-onset manifestations is unknown. So far, no cases of CRI have been reported to the CPSP. Physicians are reminded that it is important to investigate all infants born to mothers who have confirmed or suspected rubella infection during pregnancy, even if the infants have no obvious abnormalities on examination. Prenatal rubella screening and postpartum vaccination will continue to be essential in our quest to eliminate rubella infection during pregnancy.

Principal investigator
Paul Varughese, DVM, MSc, Division of Immunization and Respiratory Diseases, Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada, Tunney’s Pasture PL 0603E1, Ottawa ON K1A OL2; tel.: 613-957-1344; fax: 613-998-6413; e-mail: paul_varughese@hc-sc.gc.ca

Hemolytic uremic syndrome

Highlights
- Thirty-three percent of children with endemic diarrhea-associated hemolytic uremic syndrome required dialysis during the acute phase of illness.
- The mortality rate was 3.6%.
- One child had definitive evidence of Streptococcus pneumoniae-associated HUS and another was a possible case. Both children were dialysed and survived without apparent major sequelae.

Endemic diarrhea-associated hemolytic uremic syndrome caused by Escherichia coli O157 is a serious public health problem in Canadian children.

Background
Hemolytic uremic syndrome (HUS) is one of the leading causes of acute renal failure in many developed countries. Most commonly, HUS is associated with prodromal symptoms, including diarrhea and bloody stools. Cases may occur singly, in family outbreaks, or linked to ingestion of contaminated food or water. For example, a large waterborne outbreak in Walkerton, Ontario, in the summer of 2000, resulted in an estimated 2,000 cases of diarrheal illnesses, including 26 cases with HUS due to E. coli O157 and 119 confirmed cases of Campylobacter.

Verotoxin-producing E. coli (VTEC) infection is frequently associated with development of HUS. Nevertheless, HUS may also occur in various settings,
including invasive infections with neuraminidase producing pathogens such as *Streptococcus pneumoniae*. *S. pneumoniae*-associated HUS (SPAH) may lead to significant morbidity and mortality in children. There is an awareness of an increasing incidence of SPAH. Paediatricians participating in the CPSP were invited to report cases of HUS with prodromal diarrhea (HUS D+) and those without diarrhea (HUS D−). All detailed case reports were reviewed and those fulfilling the case definitions were included in the study.

**Objectives**

1) To determine the incidence of HUS D+ in Canadian children, including illness caused by *E. coli* O157:H7 and non-O157 strains.
2) To determine the incidence of SPAH in the same population.

**Case definitions**

**HUS D+:** Diarrhea associated with HUS

A prodrome of enteric symptoms in a child under 16 years of age with all the following:
1) Acute renal impairment with serum creatinine:
   - >50 µmol/L if <5 years
   - >60 µmol/L if 5-9 years
   - >90 µmol/L if 10-13 years
   - >110 µmol/L if >13 years
2) Microangiopathic hemolytic anemia (Hb<100g/L with fragmented red cells).
3) Thrombocytopenia (<150,000 x 10⁹/L) in the absence of septicemia, malignant hypertension, chronic uremia, collagen or vascular disorders.

**HUS D−:** *Streptococcus pneumoniae* associated with HUS (SPAH)/Renal-hematological organ failures associated to invasive *Streptococcus pneumoniae* infections (RHOF-ISP)

A child under 16 years of age with:
1) Evidence of invasive *S. pneumoniae* infection (blood or another normally sterile biological fluid: cerebrospinal, pericardial, articular, peritoneal, pleural) excluding middle ear, sinus, tracheal aspirates.
2) Both renal and hematological organ failures defined as above for HUS D+.

These should occur in the absence of chronic underlying conditions that may have accounted for renal and hematological dysfunctions.

Definite case of SPAH: evidence of thrombotic microangiopathy on renal biopsy or autopsy.

Possible case of SPAH: distinction between pneumococcal sepsis with secondary organ failures (RHOF-ISP) and SPAH will be determined through a Delphi process.

**Duration**

April 2000 to March 2002

---

**TABLE 14**

<table>
<thead>
<tr>
<th>HUS results</th>
<th>Reported</th>
<th>Conformed with case definition</th>
<th>Duplicates</th>
<th>Discards</th>
<th>Under review</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUS D+ (year 2000*)</td>
<td>122</td>
<td>76*</td>
<td>35</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>HUS D+ (year 2001†)</td>
<td>88</td>
<td>49</td>
<td>24</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>HUS D− (year 2000*)</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>HUS D− (year 2001†)</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

* From April to December 2000; † Detailed reports were available in 61 cases; ‡ From January to December 2001; § One definite and one possible case.
**Results**

This analysis covers endemic cases noted during the 21-month study period from April 2000 to December 2001. In 2000, a total of 122 cases were reported to the CPSP. Detailed case reports were received for 61 of the 76 cases, which conformed to the case definition for HUS D+ for that year. In 2001, 88 HUS D+ cases were reported, of which 49 conformed to the case definition and had detailed reports. The remaining cases are either duplicates, discards, or are still under review regarding their status.

**Seasonal variations**

The seasonal variations in the incidence of HUS D+ for the year 2000 and 2001 are presented in Figure 4. The data show that most cases occur during the summer months; this is consistent with national trends in reporting.

**Clinical data and outcomes**

A slight predominance of females (59% versus 41%) was observed. The median age of the study population was 3.7 years (0.16-15.5). Of the 110 HUS D+ cases, diarrhea was present among 98% (n=108); bloody stools were noted in 85% (n=93); vomiting occurred in 76% (n=84); a bacterial stool pathogen was identified in 70% (n=77); and *E. coli* O157 was noted in 95% (n=73).

Thirty-three percent (n=36) of cases required dialysis during the acute phase of illness. Evaluation for long-term renal impairment using the glomerular filtration rate was planned by treating physicians in 16% of the cases. Among them, five children (4.5%) with an abnormally decreased glomerular filtration rate have already been identified. Evaluation for other sequelae is pending. During the study period, the rate of mortality was 3.6% (n=4), two cases being noted during each year.

**S. pneumoniae-associated HUS**

Two out of the three cases reported in 2001 possibly met the case definition; the two reported in 2000 did not. Both patients required dialysis and survived without apparent sequelae. *S. pneumoniae* was isolated in the blood of one child, while the other showed a left lobar pneumonia with effusion. Although both cases may represent SPAH, definitive evidence was available for only one patient.

**Principal investigators**

François Proulx, MD, University of Montreal, Department of Paediatrics, Section of Intensive Care,
Background

Hepatitis C virus (HCV) is now recognized as the most common cause of chronic viral hepatitis leading to cirrhosis, end-stage liver disease and hepatic carcinoma. Although HCV infection produces a more slowly progressive disease than does hepatitis B, it accounts for twice as many fatalities.

In Canada, it is reasonably estimated that the prevalence of HCV infection is about 0.8% for a total number of 240,000 infected persons. A mathematical model predicts approximately 2,200 new cases each year; 50 to 70% are unaware of their infection. Extrapolation from the general population data in Canada suggests that up to one in 120 deliveries might occur to an HCV-infected woman. Since HCV is inefficiently spread by sexual contact, and because screening of the blood supply is now in place, the relative epidemiological importance of vertical HCV transmission will gradually increase as it becomes the only risk factor for HCV acquisition in children.

Recent studies with long-term follow-up of HCV-infected children have suggested that infection in children is associated with milder disease than in adults, but this remains controversial. The clinical course in children is characterized by low or normal transaminase levels in 50 to 60% of children, less severe histological changes and a lower percentage with persistent presence of HCV RNA. Follow-up in some of these is close to 20 years. However, some children develop fibrosis on liver biopsy even within 10 years of infection, fibrosis progresses with increasing age and duration of illness. Thus, some individuals infected in early childhood will eventually progress to end-stage liver disease. A unique feature of HCV infection in children is the possibility for a limited number of patients to spontaneously eliminate the virus.

Data derived from studies and observations are dispersed and insufficient to warrant adequate care.
and treatment for HCV-infected pregnant women. Moreover, sufficient evidence is lacking on which to base recommendations for ante-, intra- and postpartum management of HCV-infected pregnant women to prevent transmission to their offspring. In addition, there is little information on the natural history of HCV infection in children.

**Objectives**

1) To estimate the relative weight of known HCV infection among children and adolescents followed by paediatricians.

2) To establish the regional distribution of known paediatric HCV infection among provinces and territories.

3) To estimate modes of transmission of HCV (infected blood products/organ transplantation, mother to child or intravenous drug user).

4) To describe the current management of HCV-infected patients.

5) To define the natural history of HCV infection in regards to date of infection with a special interest in HCV transmission from mother to child (prospective follow-up from birth).

6) To establish a pan-Canadian clinical cohort of HCV-infected children.

7) To standardize a questionnaire in order to compare data between different regions and countries (e.g., British Paediatric Surveillance Unit).

**Case definition**

Any child from birth to 18 years of age (inclusive) who is:

a) positive for HCV by RNA PCR on two separate specimens taken two months apart after the age of one month and/or

b) HCV antibody positive over the age of 18 months (immunosuppressed HCV-infected children may have negative antibody tests).

**Duration**

February 2001 to January 2003

**Results and discussion**

Seventy-one notifications of HCV infection were received. Twenty-eight cases were accepted; 13 were refused; eight were duplicates; seven are still unconfirmed; 12 are pending and three are late reports. Among the 28 HCV-infected children, the mean age was (at the date of report) 9.78 years (min. 0.15; max. 17.62). Eleven cases were female and 17 were male. All children are alive but three are lost to follow-up. Risk factors for HCV acquisition were vertical transmission from mother to child in 14 cases, infected blood products in eight cases, one intravenous drug user (IDU), and five other less defined causes. Among 14 children vertically HCV-infected, three children were born to HIV/HCV co-infected mothers. The medical histories of mothers

<table>
<thead>
<tr>
<th>TABLE 15</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Information from HCV-infected children</strong></td>
</tr>
<tr>
<td><strong>Sex</strong></td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

35
indicate that 10 women were IDUs, two had received infected blood products, and two had an unknown risk factor. Among 28 HCV-infected children recruited during this first year, 18 (64.3%) were Caucasian, four (14.3%) were Aboriginal, two (7%) were Asian and four were from Pakistan, Armenia and Africa. Reports of HCV–confirmed cases come from six provinces: British Columbia (2 cases), Alberta (5 cases), Saskatchewan (3 cases), Manitoba (1 case), Ontario (3 cases) and Quebec (14 cases).

Conclusions
In the first 11 months of the study, less than 30 new cases of HCV infection in children and adolescents were reported (19 additional cases are being completed). The total number of cases is lower than expected with cases reported from six provinces. The Maritimes and territories did not report HCV cases. It is important to note that mother to child transmission represents half of all confirmed cases in a context where detection of HCV among pregnant women is not routine. It will be interesting to see in the second year of surveillance if the number of reported cases increases and if the trend toward mother to child transmission is confirmed.

Principal investigator
Normand Lapointe, MD, Le CHU mère-enfant, Hôpital Sainte-Justine, Research Center, 3175 ch Côte-Sainte-Catherine, Montreal QC H3T 1C5; tel.: 514-345-4836; fax: 514-345-4794; e-mail: cmis@justine.umontreal.ca

Co-investigators
Steven Martin, MD, Hôpital Sainte-Justine, Research Center
Véronique Pelletier, MD, Hôpital Sainte-Justine
Eve Roberts, MD, The Hospital for Sick Children
Richard Schreiber, MD, Children’s & Women’s Health Centre of British Columbia
Lesley J. Smith, MD, University of Alberta Hospital

Necrotizing fasciitis

Highlights
- Necrotizing fasciitis is rare in the Canadian paediatric population.
- Almost half of the group A β-hemolytic streptococcal necrotizing fasciitis cases were associated with varicella.

Background
For the past few years, the media has focused attention on a condition dubbed “flesh eating disease”, referring primarily to a form of invasive group A β-hemolytic streptococcal (GABHS) infection that leads to fascia and muscle necrosis. In 1999, the Canadian Paediatric Society issued a statement on the state of knowledge and management of children and close contacts of persons with all-invasive GABHS disease. As relatively little information is available on this condition in Canadian children, necrotizing fasciitis (NF) was added to the list of current CPSP studies in the fall of 2001 to establish actual national rates and the epidemiology of NF.

Objectives
To define the epidemiology, management and outcome of necrotizing fasciitis (NF) in Canadian
children with the following specific questions: What is the burden of both types of NF in Canadian children? Are there regional differences in rates? What are the common presenting signs and symptoms? How does management of this condition differ across the country (including supportive care, surgical management, antibiotics used and use of intravenous immunoglobulin)? How many cases of type II NF are associated with varicella? What is the morbidity associated with NF? What is the case fatality rate in the current era?

**Case definitions**

For the purpose of this study, the two types of necrotizing fasciitis (NF) will be defined as:

- **Type I NF** – Mixed infections involving anaerobes (most commonly *Bacteroides* and *Peptostreptococcus spp*) and one or more facultative anaerobes, such as streptococci (non group A β-hemolytic streptococci), and members of the Enterobacteriaceae (e.g., *Escherichia coli*, *Enterobacter*, *Klebsiella*, *Proteus*).

- **Type II NF** – Group A streptococcus isolated from either blood or the fascial tissue or both.

Definite cases of type I or type II necrotizing fasciitis will be those with histopathology demonstrating both necrosis of superficial fascia, and polymorphonuclear infiltrate and edema of the reticular dermis, subcutaneous fat and superficial fascia.

Probable cases of type I or type II necrotizing fasciitis: In the absence of examined specimens, the diagnosis will require the presence of gross fascial edema and necrosis detected at surgery, or frank cutaneous necrosis on physical examination, if surgery is not performed.

**Duration**

September 2001 to August 2003

**Results and discussion**

Since surveillance began in September 2001, seven cases of necrotizing fasciitis (NF) (five type II, one type I, and one type unknown) have been identified. Five were male and two were female (Table 16). Four of the cases were reported from Ontario, one from Quebec, and one each from Alberta and Saskatchewan. Six of the patients had surgery. One patient died. Two of the patients with type II NF had varicella infection preceding their illness. Organisms isolated in type I NF included: *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Escherichia coli* and Group B streptococcus.

The surveillance study is early, but indicates the relative rarity of this condition in children. The association of type II NF with varicella, previously reported by many investigators, was noted in almost half of all cases. The number of cases currently identified is too small to comment on issues such as the role of intravenous immunoglobulins.

**TABLE 16**

<table>
<thead>
<tr>
<th>Age of patients for necrotizing fasciitis cases reported</th>
<th>Less than one year</th>
<th>One to 10 years</th>
<th>Over 10 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>2</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Female</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

**Conclusion**

Ongoing surveillance is needed to better understand the epidemiology of paediatric NF in Canada.

**Principal investigator**

H. Dele Davies, MD, Director, Child Health Research Unit, Alberta Children’s Hospital, 1820 Richmond Rd SW, Calgary AB T2T 5C7; tel.: 403-229-7815; fax: 403-541-7508; e-mail: dele.davies@crha-health.ab.ca
Neonatal herpes simplex virus infection

Highlights

• The case fatality rate was 11% with deaths occurring only in cases with disseminated HSV infections.
• The majority of women were unaware of a history of HSV infection at the time of delivery.
• Fifty percent of the cases were HSV-1 infections. This has implications for herpes vaccine development.

These national surveillance data are of paramount importance in the development and monitoring of strategies to reduce the disease burden of neonatal herpes in Canada.

Dr. Tom Wong

Background

Genital herpes simplex virus (HSV) and neonatal HSV infections are reportable diseases in some Canadian provinces and territories; however, the epidemiological information collected through this passive surveillance system is limited. This infection is not included in the notifiable diseases system at the national level. It is therefore not possible to determine accurately the prevalence, incidence and trends of neonatal herpes infection in Canada. Data collection is essential to better understand the epidemiology and to monitor the trends. Canadian data on morbidity, mortality and on the mother and infant risk determinants will allow comparison of neonatal herpes infection rates with other countries. It will also provide baseline data before a vaccine becomes available. The information will be used to promote prevention, control program strategies, further research and to estimate the burden of illness in Canada.

HSV infections pose a serious public health concern, especially since a high proportion of these infections are unrecognized. The most serious direct consequence of genital HSV infection is the perinatal transmission from mother to infant.

The provision of an uninterrupted flow of information (between the principal investigator and reporting physician) is essential to maintaining a continuum in the surveillance and follow-up phases.

Objectives

1) To estimate the incidence rate of neonatal herpes infections (HSV-1 and HSV-2) for the years 2000 to 2003 per 100,000 live births in Canada.
2) To determine the proportion of HSV-infected infants with localized diseases, encephalitis or disseminated diseases.
3) To identify risk determinants in mothers and their maternal HSV status prior to delivery.
4) To analyze trends of cases reported over a minimum period of three years, by age, sex and province.
5) To document the morbidity/mortality of neonatal infections for the years 2001 to 2006 through a cohort study of infants identified in each of the first three years of the neonatal herpes surveillance project.

Case definition

For the purpose of this study, the neonatal period is being extended to 60 days of life so that late diagnosis is not missed. It will optimize our capacity to identify the maximum number of cases.

All cases will be laboratory-confirmed and comprise at least one of the following:

1) Culture: Isolation of herpes simplex virus (HSV-1 and HSV-2) from any site in an infant equal to or less than two months (60 days) who demonstrates one of the following:
   • Localized infection involving the skin, eyes or mouth,
• Disseminated infection:
  a) to central nervous system diseases (encephalitis)
  b) to organs other than CNS.

2) Serology: Herpes simplex virus IgM in infants equal to or less than two months (60 days) of age in conjunction with one or more of the following clinical signs: herpetic vesicular lesions to skin, mouth or eyes, keratoconjunctivitis, retinal dysplasia, chorioretinitis, cataract, encephalitis, lethargy, seizures, tremor, poor feeding, bulging fontanel, irritability, respiratory distress, jaundice, bleeding diatheses, shock, pneumonitis, disseminated intravascular coagulopathy.

A repeat serology (HSV IgM) after three or four weeks of onset of illness if test was negative initially will be acceptable.

3) PCR: On cerebrospinal fluid (CSF) and other tissues.

Duration

Phase I through the CPSP – October 2000 to September 2003

Phase II through Health Canada – Follow-up of three successive cohorts of HSV-infected infants for a period of three years each, October 2001 to September 2006.

Results and discussion

Since the study began on October 1, 2000, 61 possible cases of neonatal herpes simplex virus infection were reported; 10 in the first three months of the study and 51 in the year 2001 (Table 17). For reporting purposes, the year of diagnosis of a positive laboratory test for HSV was used.

In 2001, 18 cases were confirmed across Canada (five per 100,000 live births), with nine additional cases still under investigation. The overall demographic and health profile of the 18 confirmed neonatal HSV cases diagnosed in 2001 is summarized in Table 18 for mother and Table 19 for infant.

<table>
<thead>
<tr>
<th>TABLE 17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonatal HSV cases reported to the CPSP October 2000 to December 2001</td>
</tr>
<tr>
<td>Status</td>
</tr>
<tr>
<td>-------------------------</td>
</tr>
<tr>
<td>Confirmed NHSV*</td>
</tr>
<tr>
<td>Possible NHSV</td>
</tr>
<tr>
<td>Did not meet entry criteria†</td>
</tr>
<tr>
<td>Duplicates</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

* Including fatal cases: 2 (2001), 1 (2000), 3 (total)
† Excluded due to case definition (5), date of event prior to October 2000 (3) or no information available (1)

<table>
<thead>
<tr>
<th>TABLE 18</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSV cases diagnosed in 2001 Demographic and health profile of mother</td>
</tr>
<tr>
<td>Mean age (years)</td>
</tr>
<tr>
<td>Ethnicity:</td>
</tr>
<tr>
<td>Caucasian</td>
</tr>
<tr>
<td>Aboriginal</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>Delivery type:</td>
</tr>
<tr>
<td>Caesarian</td>
</tr>
<tr>
<td>Vaginal</td>
</tr>
<tr>
<td>Positive HSV diagnosis before delivery</td>
</tr>
<tr>
<td>HIV infected</td>
</tr>
</tbody>
</table>

Half of the neonates had laboratory confirmed diagnosis by day 13. The overall case fatality rate was 11% (29% for disseminated cases vs. 0% for localized cases, p=0.1). One of the two neonatal HSV deaths was confirmed in a male neonate with a positive HSV-2. The mother had a vaginal delivery, free of complications at 40 weeks of gestation. She was
asymptomatic at delivery and had no known history of HSV infection; she could not recall any symptoms suggestive of oral or genital HSV infection. At birth, the baby weighed 3,600 g and had an APGAR of 10 at five minutes. Even with intravenous acyclovir, the infant died at nine days of age with disseminated HSV-2 to the liver, spleen, lungs, kidneys, and CNS.

The second death occurred in a female infant diagnosed with HSV-1. The mother had a caesarian section at 39 weeks for failure to progress. At birth, the baby weighed 2,740 g and APGAR was not reported. Despite intravenous acyclovir, the infant died at nine days of age with pulmonary dissemination.

All 18 infants were started on intravenous acyclovir. Thirty-one percent (five per 16) of the surviving infants were discharged home on oral acyclovir and one infant was entered into an oral acyclovir vs. placebo trial. The impact of HSV infection and developmental impairment on the surviving children could not be assessed at the time of the initial report. Only one case was reported as having seizures and encephalitis at the time of diagnosis.

### Conclusions

Based on 18 confirmed cases in 2001, the preliminary reported neonatal herpes incidence rate in Canada was five per 100,000 live births. If the outstanding cases prove not to be neonatal herpes infections, this represents a rate that is closer to those reported by the United Kingdom (two per 100,000 live births) than by the United States (20-50 per 100,000 live births). Over a third of these infections were disseminated cases, with an overall case fatality rate of 11%. At least half of the cases were HSV-1 which has implications for herpes vaccine development. Prevention of HSV infection presents a greater challenge since the majority of women were unaware of a history of HSV infection at the time of delivery.

To evaluate the consequences of neonatal HSV infection on surviving children, it is essential, as planned in Phase II of the study, to follow the surviving children annually for at least three consecutive years.

### Principal investigator

Tom Wong, MD, Division of Sexual Health Promotion and STD Prevention and Control, Bureau of HIV/AIDS, STD and TB, Health Canada, 7th Floor, Jeanne Mance Bldg., Room 701A, Tunney’s Pasture AL:1907A4, Ottawa ON K1A 0K9; tel: 613-957-1080; fax: 613-957-0381; e-mail: Tom_Wong@hc-sc.gc.ca

### Co-investigators

Joanne Embree, MD, University of Manitoba
I.D. Rusen, MD, Health Surveillance and Epidemiology Division, Health Canada
Marc Steben, MD, Régie régionale de la santé et des services sociaux, Montréal
Sandra Burton, Division of Sexual Health Promotion and STD Prevention and Control, Health Canada

---

**TABLE 19**

<table>
<thead>
<tr>
<th>HSV cases diagnosed in 2001</th>
<th>Demographic and health profile of infant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>44%</td>
</tr>
<tr>
<td>Mean gestational age (weeks)</td>
<td>38</td>
</tr>
<tr>
<td>Median birth weight (grams)</td>
<td>2,675</td>
</tr>
<tr>
<td>Median APGAR score at 5 minutes</td>
<td>9</td>
</tr>
<tr>
<td>Median age at laboratory diagnosis (range)</td>
<td>13 days (1–31)</td>
</tr>
<tr>
<td>HSV type:</td>
<td></td>
</tr>
<tr>
<td>HSV-1</td>
<td>50%</td>
</tr>
<tr>
<td>HSV-2</td>
<td>39%</td>
</tr>
<tr>
<td>Not typed</td>
<td>11%</td>
</tr>
<tr>
<td>Classification of HSV infection:</td>
<td></td>
</tr>
<tr>
<td>Localized</td>
<td>61%</td>
</tr>
<tr>
<td>Disseminated</td>
<td>39%</td>
</tr>
</tbody>
</table>

---

**TABLE 19**

<table>
<thead>
<tr>
<th>HSV type:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HSV-1</td>
<td>50%</td>
</tr>
<tr>
<td>HSV-2</td>
<td>39%</td>
</tr>
<tr>
<td>Not typed</td>
<td>11%</td>
</tr>
</tbody>
</table>

**Classification of HSV infection:**

- **Localized:** 61%
- **Disseminated:** 39%
Neonatal liver failure/perinatal hemochromatosis

Highlights

• Neonatal liver failure is rare in Canada.
• With supportive treatment, all three infants with "chronic-pattern" neonatal liver failure survived.

Significant progress is being made in identifying patterns of severe neonatal liver disease in Canada.

Dr. Eve Roberts

Background

Neonatal liver failure is defined as severe hepatic dysfunction with coagulopathy, metabolic instability and signs of liver damage presenting in the first weeks of life. There are two predominant patterns: acute liver cell injury or chronic hepatic insufficiency. With the acute pattern, a previously normal liver suffers a severe insult, usually viral infection, for example, with Herpes simplex virus or enteric viruses such as Echoviruses. In the chronic pattern, the liver is extensively damaged and may be cirrhotic at birth: serum aminotransferase levels are typically near-normal, coagulopathy is prominent, serum albumin is low, ascites (including fetal ascites) may be present. Metabolic diseases are often associated with this chronic pattern of neonatal liver failure as well as perinatal hemochromatosis, a rare disorder with extensive hepatic and extrahepatic iron overload in the newborn. In all these “chronic-pattern” diseases, it is evident that liver damage has taken place during gestation. Although some infants with neonatal liver failure recover spontaneously, the majority do not and require specific medical intervention or liver transplantation for survival.

Objectives

1) The main objective is to obtain extensive epidemiological data about the incidence of all neonatal liver failure in Canada. These are novel data worldwide because of a relative lack of ascertainment bias.
2) A secondary objective is to determine what proportion of these cases is due to perinatal hemochromatosis. Determining more generally the etiology and natural history of neonatal liver failure will provide important and unique data and supply the relevant comparative information for assessing the etiology and natural history of perinatal hemochromatosis and may lead to more focused clinical investigations, particularly relating to therapy.

Case definitions

Occurring in an infant 60 days or less

1) Neonatal liver failure (acute pattern) – one or more of the following:
   • serum aminotransferases (AST, ALT) extremely elevated (>1,000 U/L)
   • coagulopathy despite vitamin K supplementation
   • unexplained hypoglycemia
   • serum conjugated bilirubin elevated, but jaundice may not be prominent

2) Abnormal liver function (chronic pattern) – one or more of the following:
   • serum albumin low, normal or subnormal
   • serum aminotransferases (AST) normal or mildly elevated
• coagulopathy despite vitamin K supplementation
• serum conjugated bilirubin elevated
• unexplained hypoglycemia
• liver abnormal on sonography (ultrasound)

3) Investigations relating to differential diagnosis:
• serological studies for herpes simplex, cytomegalovirus, enteric viruses (echoviruses, coxsackieviruses), parvovirus B19 [relating to congenital infections]
• serum gamma-glutamyltranspeptidase (GGT) elevated [relating to inborn errors of bile acid synthesis and progressive familial intrahepatic cholestasis types 1 and 2]
• serum amino acids profile [relating to hereditary tyrosinemia type 1]
• urinary succinylacetone [relating to hereditary tyrosinemia type 1]
• serum α-fetoprotein [relating to hereditary tyrosinemia type 1]
• MR imaging of abdomen (consistent with increased iron in liver and pancreas, but not in spleen) [relating to perinatal hemochromatosis and other disorders causing iron overload]
• serum ferritin elevated, typically >1,000 µg/L (if >20,000, must consider erythrophagocytic syndrome as alternative diagnosis) [relating to perinatal hemochromatosis]
• histopathology (salivary gland biopsy or liver biopsy) shows iron overload or other process (data not obligatory) [relating to PH and other etiologies]
• serum lactate:pyruvate ratio; urinary organic acids [relating to mitochondrial disorders]
• sweat chloride (in older infants) [relating to cystic fibrosis]
• length of time receiving total parenteral nutrition [relating to TPN cholestasis]

Duration
February 2001 to January 2004

Results
Out of the 14 reports across Canada, four definitely represent neonatal liver failure. Of these four cases, three infants had “chronic-pattern” liver failure and all three survived with supportive treatment. The fourth case was an infant with an “acute-pattern” of severe liver injury secondary to Serratia septicemia which was fatal. Five reported infants did not have neonatal liver failure, mainly because coagulopathy was not present; three cases were duplicates; and two require further data to complete the assessment. There was no definite case of perinatal hemochromatosis reported and no infant underwent liver transplantation.

Nevertheless, two important trends are seen: one infant proved to have X-linked adrenoleukodystrophy with a most unusual presentation as severe neonatal cholestatic liver disease, and two of the other infants had significant jaundice in the first 24 hours of life, a noteworthy neonatal problem deserving more analysis.

Conclusions
Significant progress has been made in identifying patterns of severe neonatal liver disease in Canada. The study is definitely beginning to achieve an important goal of the project, namely, to increase awareness of perinatal hemochromatosis and other severe neonatal liver disorders. The number of cases reported is within our expectations, given that these are rare liver disorders.

Principal investigator
Eve Roberts, MD, University of Toronto, Division of Gastroenterology and Nutrition, The Hospital for Sick Children, 555 University Ave., Toronto ON M5G 1X8; tel.: 416-813-7733; fax: 416-813-4972; e-mail: eve.roberts@sickkids.on.ca

Co-investigator
Andrew James, MD, University of Toronto
Progressive intellectual and neurological deterioration

Highlights
- Many different diagnoses can present as progressive intellectual and neurological deterioration.
- No cases of the variant form of Creutzfeldt-Jakob disorder were reported in Canada.

Cases of progressive intellectual and neurological disorders in children are rare events.

Background
An enhanced active surveillance system for progressive intellectual and neurological deterioration (PIND) was implemented to detect, prospectively, among the Canadian paediatric population, all persons with neurological conditions defined by a common presentation of PIND. Participating paediatricians and neurologists used a standard screening definition for PIND. All reported cases were reviewed by the principal investigator and classified into one of four predetermined categories. Cases with evidence of neurological and intellectual regression without known cause were reviewed by a panel of paediatric neurologists. Reported cases were also reviewed for the possibility of classic or variant Creutzfeldt-Jakob disease (vCJD). If the review panel felt that a reported case might have this disorder, it was referred to the CJD-Surveillance System (CJD-SS) team for further investigation. Cases referred to the CJD-SS were to be monitored through their lives and investigated at death, unless elements of the case warranted earlier investigation.

Objectives
1) To conduct active surveillance of the Canadian paediatric population for neurological conditions that are defined by a common presentation: progressive intellectual and neurological deterioration.
2) To investigate all reported cases of PIND to detect any cases of CJD or vCJD occurring in paediatric populations in Canada.
3) Upon identification of any case of CJD or vCJD, to conduct further investigation by enrolling the case in the Canadian CJD surveillance system.

Case definition
Inclusion criteria
Progressive deterioration for more than three months in a child less than or equal to 18 years of age, with loss of already attained intellectual and developmental abilities, and development of abnormal neurological signs.

Include (even if specific neurologic diagnoses have been made):
- metabolic disorders leading to neurological deterioration
- seizure disorders if associated with progressive deterioration
- children who have been diagnosed as having neurodegenerative conditions but who have not yet developed symptoms

Exclusion criteria
Static intellectual loss, e.g., after encephalitis, head injury or near-drowning.
Duration
July 1999 to June 2001

Results
From the onset of this project, 99 possible cases of PIND have been reported to the CPSP (41 cases from July to December 1999, 43 cases in 2000, and 15 cases from January to June 2001). Fourteen cases were duplicates. Fifty-nine cases were classified as having a progressive neurological syndrome associated with intellectual deterioration. Only one case of iatrogenic Creutzfeldt-Jakob disorder has been reported and it was due to dura mater plasty. This case in 1999 was also reported independently to the CJD-Surveillance System Canada. No cases of the variant form of Creutzfeldt-Jakob disorder were reported. Fifteen cases did not meet the above-mentioned entry criteria, while another 10 could not be classified due to a lack of clinical information needed for classification. In many cases, this was the result of the limited information that physicians provided on the original mail-back forms. While letters asking for this information often went unanswered, direct telephone conversations with the physicians proved helpful in a few cases to get missing information. Often, when contacted, the physicians had forgotten who the patient was or had referred the patient to a university centre for confirmation of diagnosis. Without consent for release of information, the physicians in the referral centres who had been asked to see the child in consultation could not release the needed information to the surveillance program for patient classification. The rate of reporting of possible cases remained fairly stable over the period of the study.

Conclusions
Cases meeting the criteria for entry into this study accrued at the expected rate. No new cases of variant Creutzfeldt-Jakob disorder were discovered. The only case of CJD reported to this surveillance program was also reported independently to the CJD-Surveillance System Canada. Cases of PIND in children are rare events.

Principal investigators
Daniel Keene, MD, Division of Neurology, Department of Paediatrics, Children’s Hospital of Eastern Ontario, 401 Smyth Rd, Ottawa ON K1H 8L1; tel.: 613-523-5154; fax: 613-523-2256

Terry Sutcliffe, Coordinator, CJD-Surveillance System Canada; tel.: 1-888-489-2999; fax: 613-952-6668; e-mail: terry_sutcliffe@hc-sc.gc.ca

Study coordinator
Ms. Pat Harman, CJD-Surveillance System Canada; tel.: 1-888-849-2999; e-mail: patricia_harman@hc-sc.gc.ca

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Number of cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitochondrial disorder</td>
<td>12</td>
</tr>
<tr>
<td>Neuronal ceroid lipofuscinosis</td>
<td>8</td>
</tr>
<tr>
<td>Mucopolysaccharidosis</td>
<td>6</td>
</tr>
<tr>
<td>Krabbe’s disease</td>
<td>4</td>
</tr>
<tr>
<td>Rett syndrome</td>
<td>4</td>
</tr>
<tr>
<td>Adrenoleukodystrophy</td>
<td>2</td>
</tr>
<tr>
<td>Cree leukoencephalopathy</td>
<td>2</td>
</tr>
<tr>
<td>Niemann-Pick disease</td>
<td>2</td>
</tr>
<tr>
<td>Vanishing white matter disorder</td>
<td>2</td>
</tr>
<tr>
<td>Alexander’s disease</td>
<td>1</td>
</tr>
<tr>
<td>Biotinidase deficiency</td>
<td>1</td>
</tr>
<tr>
<td>Hallervorden-Spatz</td>
<td>1</td>
</tr>
<tr>
<td>Gaucher type 3</td>
<td>1</td>
</tr>
<tr>
<td>Glucose transporter defect</td>
<td>1</td>
</tr>
<tr>
<td>Lafora bodies disorder</td>
<td>1</td>
</tr>
<tr>
<td>Metachromatic leukodystrophy</td>
<td>1</td>
</tr>
<tr>
<td>Subacute sclerosing panencephalitis</td>
<td>1</td>
</tr>
<tr>
<td>Undiagnosed neurodegenerative disorders</td>
<td>9</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>59</strong></td>
</tr>
</tbody>
</table>
Smith-Lemli-Opitz syndrome

Highlights

- The molecular spectrum of SLO mutations and their genetic backgrounds were determined for the Canadian population.
- Incidence results were used to support the extension of the National Institute of Health-funded multi-centre international study on prenatal screening for SLO in Ontario.

Background and rationale

Smith-Lemli-Opitz syndrome (SLO) is an inherited defect of cholesterol synthesis caused by mutations in the 7-dehydrocholesterol reductase gene (DHCR7). The enzymatic defect leads to a generalized cholesterol deficiency, and to an accumulation of the immediate precursor, 7-dehydrocholesterol (7-DHC), in all body tissues, resulting in a characteristic syndrome of multiple malformations, dysmorphic features, mental retardation, and behavioural abnormalities. SLO is readily diagnosed by demonstration of elevated levels of the cholesterol precursor 7-DHC that accumulates in body fluids and tissues of these patients. The use of biochemical diagnostic test for SLO has led to the diagnosis of SLO in fetuses and in infants with multiple or lethal anomalies that previously defied diagnosis, as well as in individuals who have significant mental retardation and behavioural abnormalities, but minimal physical features. Many of the latter group of patients escaped detection for long periods of time; some were diagnosed with idiopathic mental retardation, pervasive developmental disorder, or autism. The behavioural phenotype of SLO is characterized by autistic features, tactile defensiveness, and significant sleep disturbance among other features. Treatment of SLO with dietary cholesterol supplementation has shown promise with improvement in the general health, as shown by reduction of frequency of infections, improved growth, and significant improvement in behaviour. Families of children with SLO treated with cholesterol supplementation report great improvement in the quality of life in addition to the physical improvements. It is possible that early institution of treatment may improve the final developmental outcome of patients with SLO; thus, if SLO has a sufficiently high incidence, newborn screening of SLO may be indicated.

Objectives

1) To determine the incidence and prevalence of inherited deficiency of 7-dehydrocholesterol reductase in Canada by ascertaining all newly diagnosed cases of SLO.
2) To determine whether prenatal and neonatal screening for SLO is indicated in Canada.
3) To obtain demographic and medical information on patients with SLO and to assemble a database for demographic studies and future research use (e.g., evaluation of dietary and medical therapies, genotype-phenotype correlation).

Case definitions

Confirmed case

Elevated concentration of 7-dehydrocholesterol (7-DHC) in plasma (postnatal), or in chorionic villus sample or amniotic fluid (prenatal), or in blood spots obtained as part of neonatal screening.

Probable case (requires biochemical or DNA confirmation):

A. Infant/child/adult with developmental delay/mental retardation, with behavioural abnormalities/attention deficit hyperactivity disorder (ADHD)/
autistic features, with normal chromosomes, and any two of the following features:
  i. 2-3 toe syndactyly (webbing)
  ii. index finger clinodactyly (‘zig-zag’ index finger)
  iii. abnormal facial features (epicanthal folds, short nose, micrognathia)
  iv. ptosis
  v. genital anomalies in the male
  vi. failure to thrive
  vii. feeding difficulties requiring gavage tube feeding

B. Stillbirth or newborn with normal chromosomes and any two of the following features:
  i. ambiguous genitalia/genital anomalies in male infant/female external genitalia in an infant with normal male chromosomes
  ii. abnormal facial features (epicanthal folds, short nose, micrognathia)
  iii. cleft palate/submucous cleft
  iv. polydactyly of hands or feet
  v. lobster hand deformity or missing fingers of hand
  vi. 2-3 toe syndactyly (webbing)
  vii. internal anomalies (any of the following: cystic renal dysplasia, nervous system malformations, unilobar lungs, adrenal lipid accumulation, cardiovascular malformations, punctate stippling of epiphyses)
  viii. low unconjugated estriol on maternal serum screening during the second trimester of pregnancy

C. Previous clinical diagnosis of SLO without documented elevation of 7-DHC or known 7-DHC reductase mutations

Duration

January 2000 to December 2002

Results

<table>
<thead>
<tr>
<th>Year</th>
<th>Reported</th>
<th>Confirmed</th>
<th>Duplicates</th>
<th>Discarded</th>
<th>Pending</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>36</td>
<td>19</td>
<td>9</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>2001</td>
<td>32</td>
<td>11</td>
<td>13</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Total</td>
<td>68</td>
<td>30</td>
<td>22</td>
<td>10</td>
<td>6</td>
</tr>
</tbody>
</table>

Discussion

During year one, nine confirmed new cases, born or predicted-to-be born between November 14, 1999 and October 18, 2000 were reported, yielding an expected incidence of one in 37,100 births across Canada. All of the cases of SLO were reported in infants of European Caucasian origin, suggesting that the incidence of SLO in Canadians of European Caucasian origin is one in 29,700. This trend was observed during year two, as well.

This rate of diagnosis/reporting of patients with severe SLO fell within the expected range. However, there was only one report of a birth of a child with mild SLO in year I with no subsequent reports in year II, again underscoring the delays in the diagnosis of patients with mild SLO.

All of the patients reported to the CPSP and confirmed to have SLO underwent mutation analysis to detect mutations causing SLO. The mutation spectrum of SLO in Canadian patients was determined as well as the underlying genetic background for a number of these mutations. Three new DHCR7 mutations were identified.

SLO has been removed from the area of esoteric. It is hoped that increased clinical awareness will improve the rate of diagnosis of SLO, especially of the mild cases, and that individuals with SLO will benefit directly as a result of the education provided through the CPSP.

Data results on incidence were used to support the extension of the National Institute of Health-funded multi-centre international study on prenatal screening for SLO in Ontario.

Principal investigator

Małgorzata J.M. Nowaczyk, MD, McMaster University, Department of Pathology and Molecular Medicine, Department of Paediatrics, Room 3N16, McMaster University Medical Centre, 1200 Main St W, Hamilton ON L8S 4J9; tel.: 905-521-5085; fax: 905-521-2651; e-mail: nowaczyk@hhsc.ca
New Studies in 2002

Adverse drug reactions

Adverse drug reactions (ADR) are an important cause of childhood morbidity and mortality; yet, the true incidence of this problem is poorly defined due to the lack of reporting. Pre-marketing trials often do not include children who may be at risk for unique ADRs or an increased frequency of ADRs compared with the general population. Other factors, such as the inability of children to evaluate and express their own response to medications, also increase the risk of ADRs in the paediatric population.

The CPSP is well positioned to detect ADRs in children. This study will investigate the potential of utilizing active surveillance methodologies, as is provided by the CPSP, to generate a sufficient number of cases from a large and geographically diverse paediatric population to derive meaningful data in the study of serious and life-threatening ADRs in children.

For this study, a serious and life-threatening ADR (either anticipated or unexpected) has been defined as a noxious and unintended response to a drug which occurs at any dose and results in inpatient hospitalization, prolonged hospitalization, persistent or significant disability, or death.

Duration

Fall 2002 to fall 2004

Principal investigator

Bruce Carleton, PharmD, Faculty of Pharmaceutical Sciences, University of British Columbia, Pharmaceutical Outcomes Programme, Children’s & Women’s Health Centre of British Columbia, 4480 Oak St, Vancouver BC V6H 3V4; tel.: 604-875-2179; fax: 604-875-2494; e-mail: bcrltm@interchange.ubc.ca

Co-investigators

Joe Reisman, MD, Department of Paediatrics, University of Ottawa
Anne Smith, BSc (Pharm), MSc, Pharmaceutical Outcomes Programme, Children’s & Women’s Health Centre of British Columbia
Margaret Zimmermann, BSc, Paediatric Monitoring Project, Bureau of Licensed Product Assessment, Health Canada

Neonatal hyperbilirubinemia – severe

Left unchecked, severe neonatal hyperbilirubinemia can cause significant long-term neurodevelopmental morbidity. An improved understanding of the etiology and risk factors would assist in the management and prevention of this disease.
As recognized by national guidelines of the American Academy of Pediatrics and the Canadian Paediatric Society’s Fetus and Newborn Committee, severe neonatal hyperbilirubinemia, though a rare event, is known to be associated with significant long-term morbidity. In the neonatal period, it may result in bilirubin encephalopathy and sometimes death. During the acute phase of bilirubin encephalopathy, infants present with lethargy, hypotonia and a poor sucking reflex. If the hyperbilirubinemia is not treated promptly, infants become hypertonic and may develop a fever and a high-pitched cry. The hypertonia is manifested by backward arching of the neck (retrocollis) and trunk (opisthotonus). On autopsy, deposition of bilirubin is noted in the basal ganglia and various brainstem nuclei; this pathological entity is termed “kernicterus” (yellow staining of the brain).

If infants survive the acute phase, they are at risk of developing chronic encephalopathy and present with athetoid cerebral palsy, sensori-neural hearing loss, dental dysplasia, paralysis of upward gaze and, less often, with intellectual and other handicaps later in life. Since the use of Rh immunoglobulin and intrauterine transfusion, the incidence of bilirubin encephalopathy secondary to Rh disease has decreased significantly. However, other causes, including ABO hemolytic disease and G6PD deficiency, can present with severe hyperbilirubinemia in the neonatal period. Reports of bilirubin encephalopathy associated with extremely high serum bilirubin levels have started to emerge in the past few years.

The CPSP offers the opportunity to assess the frequency, etiology, and risk factors associated with severe hyperbilirubinemia in neonates: information not currently well documented in Canada. The epidemiological data will identify strategies for risk reduction and help assess the potential value of a routine G6PD deficiency screening program in neonates and a routine blood group typing and Coombs analysis from cord blood.

**Duration**
July 2002 to June 2004

**Principal investigator**
Michael Sgro, MD, Department of Paediatrics, 15th Victoria-014, St. Michael’s Hospital, 30 Bond St, Toronto ON M5B 1W8; tel.: 416-864-6060, ext. 6560; fax: 416-867-3736; e-mail: sgrom@smh.toronto.on.ca

**Co-investigator**
Vibhuti Shah, MD, Department of Paediatrics, Mount Sinai Hospital

**Prader-Willi syndrome**

 Identification of the Canadian incidence of Prader-Willi syndrome is important in identifying the burden, both medical and economic, of this challenging condition.

Dr. Glenn Berall

Prader-Willi syndrome (PWS) is a rare (1:15,000) multisystem genetic disorder that leads to hyperphagia and obesity. The major findings include: hypotonia, obesity, hypogonadism, hypomentia, hyperphagia, and characteristic facial appearance (narrow bifrontal diameter, almond shaped eyes, thin
philtrum). Despite its rarity, early diagnosis, by an aware physician, and appropriate management can have a positive impact on the patient’s health and quality of life, particularly regarding prevention of morbid obesity and its treatable and potentially fatal consequences. However, many diagnoses are delayed, often well into adulthood.

The CPSP provides a great opportunity to determine the incidence of diagnosed PWS in Canada, the incidence of obesity in PWS and its consequences, as well as the incidence of other manifestations included in the major and minor diagnostic criteria. Furthermore, the CPSP offers the challenging opportunity to create awareness in the scientific community of the existence of the disease and the availability of clinical and cytogenetic/molecular diagnostic criteria.

Knowing the Canadian PWS clinical status and understanding the depth of the challenge will help with future health-care planning, particularly on a population basis. Early diagnosis of PWS is relevant because it allows for judicious intervention and potential prevention of sequelae.

**Duration**
Fall 2002 to fall 2004

**Principal investigator**
Glenn B. Berall, MD, Chief of Paediatrics, University Health Network, Toronto Western Hospital, 399 Bathurst St, Toronto ON M5T 2S8; tel.: 416-603-5800, ext. 2962; fax: 416-603-5180; e-mail: Glen.Berall@uhn.on.ca

**Co-investigators**
Maria Virginia Desantadina, MD
Judith Allanson, MB, ChB, Children’s Hospital of Eastern Ontario

---

**Vitamin D deficiency rickets**

The goal of this study is to provide current epidemiological data in order to develop novel public health measures for the prevention of vitamin D deficiency among Canadian children.

Vitamin D is critical for calcium homeostasis and for mineralization of the skeleton, especially during the growing years. A deficiency in vitamin D is costly for the paediatric patient, as it leads to a mineralization defect at the epiphyseal growth plates (rickets) and in bone tissue (osteomalacia). These effects are associated with pain, fractures, skeletal deformity, growth retardation, dental enamel defects, delayed developmental milestones and, in severe cases, hypocalcemic tetany and seizures. If not recognized and treated, vitamin D deficiency may have long-term sequelae. On the other hand, the disease is entirely preventable with simple dietary measures or vitamin supplementation.

The two main sources of vitamin D are skin exposure to sunshine and dietary intake. Due to our northern latitude in Canada, infants and children cannot depend on adequate skin exposure to sunlight for vitamin D synthesis. Therefore, as a regulated public health measure, all fluid dairy products, excluding yogurt drinks, are fortified with vitamin D. Human milk, advocated by paediatricians as the ideal fluid source for infants in the first year of life, is not a rich source of vitamin D. As such, the Canadian Paediatric Society has recommended that all
exclusively breast-fed infants receive a daily supplement of oral vitamin D. In addition, recommendations in Canada’s Food Guide encourage older children to maintain a diet adequate in calcium and vitamin D.

Despite these public health measures, vitamin D deficiency among children has been documented in Canadian medical literature. The etiology of vitamin D deficiency rickets in Canada over the past decade is likely multi-factorial. First, not all health-care providers/parents of breast-fed infants are aware that vitamin D supplementation is necessary for rickets prevention. Furthermore, adequate nutrition and vitamin supplementation are not readily available to some children, such as those living in poverty and in the Canadian immigrant and First Nations communities. Third, health food alternatives given to infants and children with severe allergies and eczema may result in dietary deficiency of calcium and vitamin D. Finally, the prevention of excessive ultra-violet radiation in childhood through sunscreen programs has contributed to the rise in rickets worldwide.

The CPSP offers a comprehensive method to establish the incidence, etiology, and geo-ethnic distribution of vitamin D deficiency rickets among children living in Canada. For cases identified, information pertaining to the child’s nutritional status, vitamin D intake, ethnicity, skin colour, geographic location and clinical presentation will be obtained. The ultimate goal of this study is to provide the medical and public health communities with unique and current epidemiological data in order to foster the development of novel public health measures for the prevention of this disease.

**Duration**

July 2002 to June 2004
**International Developments**

The International Network of Paediatric Surveillance Units (INoPSU), established in 1998 to enhance collaboration between units from four continents, provides a unique opportunity for simultaneous cross-sectional studies of rare diseases in populations with diverse geographic and ethnic characteristics.

Currently worldwide, there are 11 national paediatric surveillance units that are members of INoPSU, representing a population of 51 million children under the age of 15 years. Over 8,500 clinicians are asked each month to identify cases of rare or uncommon diseases in a childhood population. Participants in the Canadian Paediatric Surveillance Program (CPSP) represent 27.1% of these clinicians.

The first formal INoPSU meeting was held in Ottawa in June 2000. Joint collaborative studies are seen as an important method of advancing the knowledge of uncommon childhood disorders around the world. Though there are definite challenges, having an opportunity to meet colleagues and discuss practicalities and difficulties provides the stimulus to forge ahead.

It is anticipated that Ireland, Portugal and Greece will apply for INoPSU membership in the near future. The Czech Republic has also shown an interest.

INoPSU, through Dr. Victor Marchessault, applied and was accepted for membership in the International Pediatric Association (IPA) at their September 2001 meeting in Beijing. The IPA will be used as a means to promote international surveillance and to encourage other countries to establish surveillance units.

### TABLE 22

<table>
<thead>
<tr>
<th>Studies</th>
<th>National paediatric surveillance units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal injury due to child abuse</td>
<td>BPSU</td>
</tr>
<tr>
<td>Acute flaccid paralysis</td>
<td>APSU, CPSP, NSCK, NZPSU, PNGPSU, SPSU</td>
</tr>
<tr>
<td>Acute rheumatic fever</td>
<td>SPSU</td>
</tr>
<tr>
<td>Adverse effects from complementary or alternative medicine</td>
<td>APSU</td>
</tr>
<tr>
<td>Aplastic anaemia</td>
<td>LPSU</td>
</tr>
<tr>
<td>Anaphylaxis</td>
<td>CPSP</td>
</tr>
<tr>
<td>Atypical mycobacterial infections</td>
<td>NSCK</td>
</tr>
<tr>
<td>Cerebral edema in diabetic ketoacidosis</td>
<td>CPSP</td>
</tr>
<tr>
<td>Cerebral vascular disease/stroke &amp; like illness</td>
<td>BPSU</td>
</tr>
<tr>
<td>CHARGE association/syndrome</td>
<td>APSU, CPSP</td>
</tr>
<tr>
<td>Childhood tuberculosis</td>
<td>WPSU</td>
</tr>
<tr>
<td>Childhood inflammatory bowel disease</td>
<td>NSCK</td>
</tr>
<tr>
<td>Congenital adrenal hyperplasia</td>
<td>NSCK</td>
</tr>
<tr>
<td>Congenital cytomegalovirus infection</td>
<td>APSU, BPSU</td>
</tr>
<tr>
<td>Congenital heart disease</td>
<td>MPSU</td>
</tr>
<tr>
<td>Congenital hypothyroidism</td>
<td>LPSU, PNGPSU</td>
</tr>
<tr>
<td>Congenital rubella</td>
<td>APSU, BPSU, CPSP, NZPSU, SPSU</td>
</tr>
<tr>
<td>Congenital syphilis</td>
<td>LPSU</td>
</tr>
<tr>
<td>Diabetes mellitus/insulin-dependent/≤5 years</td>
<td>ESPED, LPSU, NSCK, PNGPSU, PPSU, WPSU</td>
</tr>
<tr>
<td>Duchenne muscular dystrophy</td>
<td>MPSU</td>
</tr>
<tr>
<td>Fetal alcohol syndrome</td>
<td>APSU, NZPSU</td>
</tr>
<tr>
<td>Fatal/near fatal asthma</td>
<td>MPSU</td>
</tr>
<tr>
<td>GLUT 1-deficiency/de novo disease</td>
<td>ESPED</td>
</tr>
</tbody>
</table>
### CPSP 2001 Results

<table>
<thead>
<tr>
<th>Studies</th>
<th>National paediatric surveillance units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group B streptococcal infection (neonatal)</td>
<td>LPSU</td>
</tr>
<tr>
<td>&lt;3months invasive disease</td>
<td>NSCK</td>
</tr>
<tr>
<td>Haemolytic uremic syndrome</td>
<td>ESPED</td>
</tr>
<tr>
<td>Haemorrhagic disease of the newborn (Vitamin K deficiency bleeding)</td>
<td>APSU, BPSU, ESPED, NZPSU</td>
</tr>
<tr>
<td>Hepatitis C virus infection</td>
<td>ESPED</td>
</tr>
<tr>
<td>Histioctysis X</td>
<td>LSU</td>
</tr>
<tr>
<td>HIV/AIDS +/- perinatal exposure to HIV</td>
<td>APSU, BPSU, MPSU, NSCK, NZPSU</td>
</tr>
<tr>
<td>Hodgkin’s disease</td>
<td>LPSU</td>
</tr>
<tr>
<td>Hospitalized pertussis in infants</td>
<td>NSCK, APSU</td>
</tr>
<tr>
<td>Idiopathic juvenile osteoporosis</td>
<td>ESPEP</td>
</tr>
<tr>
<td>Idiopathic and congenital nephrotic syndrome</td>
<td>APSU</td>
</tr>
<tr>
<td>Importation diseases: malaria, schistosomiasis, leishmaniasis</td>
<td>ESPEP</td>
</tr>
<tr>
<td>Ingestion of lamp oil (intoxications)</td>
<td>ESPEP</td>
</tr>
<tr>
<td>Intersexuality and severe genital malformations</td>
<td>ESPEP</td>
</tr>
<tr>
<td>Invasive Haemophilus influenza infection</td>
<td>ESPEP</td>
</tr>
<tr>
<td>Ischaemic stroke in infants (neonatal sinus venous thrombosis)</td>
<td>ESPEP</td>
</tr>
<tr>
<td>Kawasaki disease</td>
<td>NZPSU, PPSU</td>
</tr>
<tr>
<td>Kernicterus</td>
<td>ESPEP</td>
</tr>
<tr>
<td>Leukaemia: ALL, AML</td>
<td>LPSU</td>
</tr>
<tr>
<td>Munchausen by proxy syndrome</td>
<td>APSU</td>
</tr>
<tr>
<td>Necrotizing fasciitis</td>
<td>ESPEP</td>
</tr>
<tr>
<td>Neonatal alloimmune thrombocytopenia</td>
<td>NSCK</td>
</tr>
<tr>
<td>Neonatal herpes simplex virus infection</td>
<td>CPSP</td>
</tr>
<tr>
<td>Neonatal liver failure/perinatal hemochromatosis</td>
<td>CPSP</td>
</tr>
<tr>
<td>Neonatal meningitis</td>
<td>MPSU</td>
</tr>
<tr>
<td>Neural tube defects</td>
<td>NSCK, SPSU</td>
</tr>
<tr>
<td>Neurological endemic cretinism</td>
<td>PNGPSU</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>LPSU</td>
</tr>
<tr>
<td>Paediatric malignancies</td>
<td>PNGPSU</td>
</tr>
<tr>
<td>Palliative care</td>
<td>WPSU</td>
</tr>
<tr>
<td>Phenylketonuria</td>
<td>LPSU</td>
</tr>
<tr>
<td>Pigbel</td>
<td>PNGPSU</td>
</tr>
<tr>
<td>Pneumococcal sepsis/meningitis</td>
<td>ESPEP</td>
</tr>
<tr>
<td>Progressive intellectual and neurological deterioration (including CJD)</td>
<td>BPSU, CPSP</td>
</tr>
<tr>
<td>Renal tubular acidosis</td>
<td>PNGPSU</td>
</tr>
<tr>
<td>Rett syndrome</td>
<td>APSU</td>
</tr>
<tr>
<td>Keye syndrome</td>
<td>LPSU</td>
</tr>
<tr>
<td>Rotavirus infection</td>
<td>NSCK</td>
</tr>
<tr>
<td>RSV disease requiring intubation and artificial ventilation; severe</td>
<td>ESPEP, SPSU</td>
</tr>
<tr>
<td>Septo-optic dysplasia</td>
<td>WPSU</td>
</tr>
<tr>
<td>Severe combined immunodeficiency</td>
<td>APSU</td>
</tr>
<tr>
<td>Severe complications of medical therapy</td>
<td>NSCK</td>
</tr>
<tr>
<td>Smith-Lemli-Opitz syndrome</td>
<td>CPSP</td>
</tr>
<tr>
<td>Steroid resistant nephrotic syndrome</td>
<td>ESPEP</td>
</tr>
<tr>
<td>Splenectomy and hypersplenism</td>
<td>WPSU</td>
</tr>
<tr>
<td>Subacute sclerosing panencephalitis</td>
<td>PNGPSU</td>
</tr>
<tr>
<td>Subdural haemorrhage</td>
<td>NZPSU, WPSU</td>
</tr>
<tr>
<td>Tick-borne encephalitis</td>
<td>SPSU</td>
</tr>
<tr>
<td>Transient myeloproliferative syndrome in newborns with Down syndrome</td>
<td>ESPEP</td>
</tr>
<tr>
<td>Varicella/zoster infection</td>
<td>SPSU</td>
</tr>
<tr>
<td>Venous thromboembolic complaints</td>
<td>BPSU</td>
</tr>
</tbody>
</table>

**Legend:**

- APSU: Australian Paediatric Surveillance Unit
- BPSU: British Paediatric Surveillance Unit
- CPSP: Canadian Paediatric Surveillance Program
- ESPED: German Paediatric Surveillance Unit
- LPSU: Latvian Paediatric Surveillance Unit
- MPSU: Malaysian Paediatric Surveillance Unit
- NSCK: Netherlands Paediatric Surveillance Unit
- NZPSU: New Zealand Paediatric Surveillance Unit
- PNGPSU: Papua New Guinea Paediatric Surveillance Unit
- PPSU: Portuguese Paediatric Surveillance Unit
- SPSU: Swiss Paediatric Surveillance Unit
- WPSU: Welsh Paediatric Surveillance Unit
Highlights from other national paediatric surveillance units

Australia
Hospitalized pertussis in infancy, studied in 2001, identified that pertussis continues to cause significant morbidity and mortality in unimmunized or partially immunized infants less than six months of age. Ninety-one percent of affected infants were less than two months of age, and of the 39 affected infants eligible for immunization, 27 (69%) had received only one pertussis immunization. Contact with another person with a coughing illness that could be consistent with pertussis was identified in 55% of infants, the majority of contacts (65%) being adults. With high (90%) childhood immunization levels, adult family members are now an important source of pertussis infection.

Britain
The progressive intellectual and neurological deterioration (PIND) study is now in its sixth year. Variant Creutzfeldt-Jakob disease remains high on the public health agenda in this country, and increasingly in the global context, as four vCJD cases have been identified in people living outside the United Kingdom, and bovine spongiform encephalopathy has been found in cattle in 15 other countries. Over 1,000 cases of PIND, including six children with vCJD, have been reported to the study. Two of these were reported in the last six months, so the emergence of more childhood cases remains a strong possibility. In the light of an unknown incubation period and questions surrounding possible modes of transmission, a longer surveillance period is warranted in order to accurately monitor and document the emergence of vCJD in children.

Germany
Since 1996 in Germany, primary infant immunization against Haemophilus influenzae has been most commonly given in the form of diphtheria-tetanus toxoids-acellular pertussis/H. influenzae type b (DTaP/Hib) or diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b (DTaP-IPV/Hib) combination vaccines. These combination vaccines elicit lower anti-Hib antibody concentrations than the equivalent Hib conjugate administered as a separate injection, but the clinical relevance of this phenomenon is unknown.

To assess the impact of DTaP/Hib combination vaccines on the incidence of invasive Hib disease in Germany, two independent surveillance systems, one hospital- and one laboratory-based, were used during 1998 and 1999 for detection of cases. Vaccination histories of all cases detected were obtained by telephone contact with parents or health-care providers. During the two-year study period, invasive H. influenzae disease in the under-five-year age group continued to fall, with a mean annual incidence of 1.01 per 100,000 children. National vaccination coverage rates revealed that only 70% of children given DTaP/Hib or DTaP-IPV/Hib received the recommended three doses in their first year of life, but the overall effectiveness of these vaccines was high at 97.5% (95% CI ± 96.3-98.4) for those who had received at least one dose. In subjects who received the full three-dose schedule, effectiveness was 98.8% (95% CI ± 98.2-99.3).

Although it is well documented that DTaP/Hib vaccines elicit lower anti-Hib titres than separate vaccines, such combinations are effective in reducing the incidence of invasive H. influenzae type b disease.
This study, entitled “Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (–inactivated poliovirus)/H. influenzae type b combination vaccines”, was published in *Pediatr Infect Dis J* 2001;20(8):767-74.

Ireland

The incidence of insulin-dependent diabetes is subject to wide international variation. Reported incidence rates range from 0.6 per 100,000 per year in Korea and Mexico City to 45.3 per 100,000 per year in Finland. Little data is available for Ireland. A BPSU study in 1988 showed Ireland to have one of the lowest incidence rates in Europe at 6.8 per 100,000 per year. However, there was concern that this data could be incomplete.

A prospective study was undertaken in 1997, through the Irish Paediatric Surveillance Unit (IPSU), to calculate the national incidence rate for insulin-dependent diabetes mellitus presenting under the age of 15 years. Participating paediatricians were asked to notify all new cases of diabetes under the age of 15 presenting to them, using an active monthly reporting card system. Paediatricians who reported cases to the IPSU were sent a questionnaire to complete, and those who did not report cases of diabetes were contacted to ensure no cases had been seen. A second independent source of case identification was employed using central government data.

The results of this study show that the crude incidence of diabetes under the age of 15 years was 16.6 per 100,000 per year (95% CI 13.9-19.5). The directly standardized incidence rate was 16.3 per 100,000 per year (95% CI 14.2-18.5). The age specific rates were: 10.8 (7.1-15.7); 21.3 (16.2-27.4); and 17.0 per 100,000 per year (12.8-22.2) for the age groups 0-4.99; 5-9.99; and 10-14.99 years respectively.

This study suggests that Ireland has a moderately high incidence of diabetes in children below 15 years and not a low incidence of the disease as previously reported. This finding has implications for health policy planning and further epidemiological study. The establishment of a diabetes register is recommended in Ireland to monitor the incidence of this important disease.

Latvia

The Latvian Paediatric Surveillance Unit's population includes 534,100 children under the age of 18 years. In 2001, the program claimed a 70% response rate and published a literature review on the pneumococcal etiology of HUS in *Latvijas Pediatrs*. Anaphylaxis is being considered for inclusion in the program effective July 2002.

Malaysia

The Malaysian Paediatric Surveillance Unit, established in 1994 under the aegis of the Malaysian Paediatric Association, has relocated to Kuala Lumpur. Presently suspended, the unit hopes to be functioning again by mid-2002.

Netherlands

Thanks to the surveillance unit, the adrenogenital syndrome (AGS) screening proved to be 100% reliable and was implemented nationwide. Again the reports of diabetes showed that there was a strong rise, especially in children less than five years of age (doubled in five years) and in immigrants. Further studies are urgently needed to clarify this increase.

New Zealand

The New Zealand Paediatric Surveillance Unit continues to function well with a high participation
and response rate. As well as undertaking active surveillance of acute flaccid paralysis for the Ministry of Health, a number of other conditions are being studied to satisfy the World Health Organization’s polio surveillance requirements. Importantly, all participating paediatricians are given the opportunity to use the network to undertake studies of their own – assuming that scientific and ethical criteria are met – as witnessed by the breadth of studies now undertaken. Being a small country, there is a continual need to balance between studying conditions that are common enough to generate sufficient numbers to gain information, and not overloading the clinicians with multiple requests for information.

A recent highlight has been the completion of the childhood diabetes study. Diabetes mellitus (DM) was studied for the two-year period 1999 to 2000 in children and adolescents under 15 years of age. The average annual incidence of type 1 DM was 17.9 per 100,000, which represents a doubling in incidence since 1972. The incidence was significantly higher in the South Island compared to the North Island. There was also a significant difference between Maori and Non-Maori, the Non-Maori rate being 4.5 times higher than the Maori rate. Due to a higher proportion of Non-Maori residing in the South Island, the geographical difference noted above disappears after adjusting for ethnicity.

In addition, 12 (3.8%) cases of type 2 DM were reported, along with five cases of other specific types (two of probable maturity onset diabetes of the young, one of cystic fibrosis, one of Prader-Willi and one of a mitochondrial disorder).

The findings are in keeping with international reports of an increase in the incidence of type 1 DM, and the emergence of type 2 DM in this young population, and have major implications for the delivery of health services, both now and in the future.

### Papua New Guinea

Anecdotal and published information suggest a low incidence and prevalence of type 1 diabetes in Papua New Guinea (PNG). Incidence and prevalence were followed prospectively from July 1996, using the PNGPSU (paediatric surveillance unit). No children were receiving insulin in PNG at the start of the period. Over the next 4.5 years, eight cases were reported, an annual incidence of 0.08 per 100,000 and a prevalence of 0.28 per 100,000 in children less than 15 years of age. These figures are as low as any reported elsewhere. Three cases were from the small expatriate population. All cases in Melanesian children posed significant management problems, with two children dying during the study period.

This study, entitled “Insulin-dependent diabetes”, was accepted for publication in the Papua New Guinea Medical Journal.

### Portugal

The Portuguese Paediatric Surveillance Unit (PPSU), established in June 2000, commenced in March 2001 with a circulation of over 2,000 paediatric members of the Portuguese Paediatric Society. Conditions currently under study include: haemolytic uremic syndrome, Kawasaki disease, insulin-dependent diabetes mellitus under five years of age, and group B streptococcal infection in the first three months of life. The PPSU has recently sought affiliation to INoPSU and this is currently under consideration.

### Switzerland

Hemolytic uremic syndrome (HUS) in children has been on the SPSU program since April 1, 1997. Every patient under 17 years of age with a clinical and biochemical diagnosis of HUS (acute haemolytic anemia, thrombocytopenia, renal failure) is included in the study. In 2001, 13 cases were recorded of which 10 were children less than five years of age. Ten cases occurred after a diarrheal prodrome, with cultures and/or toxins positive for VTEC in four
cases. Two cases with respiratory prodromal symptoms were associated with an invasive pneumococcal disease, one of them fatal.

Wales
A population-based incidence study was undertaken in Wales and the United Kingdom for two years, from April 1996 to March 1998 to: 1) ascertain the incidence and nature of severe physical child abuse in Wales; 2) ascertain the incidence of all physical abuse in babies under one year of age; and 3) determine whether child protection registers accurately reflect the number of children who are physically abused.

Children under 14 years of age were studied with severe physical abuse consistent with the criminal law level of grievous bodily harm. This included the following seven categories of injury: death; head injury, including subdural haemorrhage; internal abdominal injury; physical injury in Munchausen syndrome by proxy, including suffocation; fracture; burn or scald; adult bite. Cases were ascertained through the Welsh Paediatric Surveillance Unit (WPSU). (A criterion for inclusion was a multidisciplinary agreement that physical abuse had occurred [at a case conference, strategy meeting or Part 8 Review]). The incidence of all babies under one year of age with physical abuse was also studied. Ascertainment of babies below one year of age was undertaken from Child Protection Registers (CPRs), as well as through the WPSU.

Severe abuse is six times more common in babies 54 per 100,000 per year (95% CI ± 17.2) than in children from one to four years of age 9.2 per 100,000 (95% CI ± 3.6). It is 120 times more common than in children five to 13 years old 0.47 per 100,000 (95% CI ± 0.47). This is mainly due to two types of serious abuse (brain injury, including subdural haemorrhage, and fractures) being more common in babies under the age of one year than in older children. Using data from two sources (the WPSU and CPRs), the incidence of physical abuse in babies is 114 per 100,000 (95% CI 114 ± 11.8) per year. This equates to one baby in 880 being abused in the first year of life. The largely rural health authority area in Wales had incidence figures for abuse in babies that were 50% of the three other predominantly urban health authority areas. Boys throughout the series were more at risk of being severely abused than girls (p<0.025). Only 29% of the babies less than one year of age on the child protection register had actually been injured. Thirty percent of abused babies under the age of one year and 73% of severely abused children over the age of one year had caused previous concern to health professionals regarding abuse or neglect.

Physical abuse is a significant problem in babies under the age of one year. Very young babies (less than six months of age) have the highest risk of suffering damage or death due to physical abuse. Severe abuse, in particular subdural haematoma and fracture, is much more common in babies than in older children. There is evidence of failure of secondary prevention of child abuse by health professionals, with a greater need to act on concerns regarding abuse and neglect. Interagency child protection work in partnership with parents should focus more on protecting babies less than one year of age from further abuse than on keeping the infant within an abusive home. The Child Protection Register is not intended as an accurate measure of children suffering abuse. It is a record of children requiring a child protection plan and must not be used as a measure of numbers of abused children.

This study, entitled “The Incidence of Severe Physical Child Abuse and Neglect in Wales”, was published in Child Abuse and Neglect April 2002.